

OFFICERS

President Paul H. Earley, MD, DFASAM President-Elect William F. Haning, III, MD, DFAPA, DFASAM Vice President Yngvild K. Olsen, MD, MPH, DFASAM Secretary Jeffrey Selzer, MD, DFASAM Treasurer Kenneth I. Freedman, MD, MS, MBA, FACP, DFASAM Immediate Past President Kelly J. Clark, MD, MBA, DFAPA, DFASAM

BOARD OF DIRECTORS

Directors-at-Large Anthony Albanese, MD, DFASAM Adam J. Gordon, MD, MPH, FACP, DFASAM Brian Hurley, MD, MBA, DFASAM Margaret Jarvis, MD, DFASAM Marla D. Kushner, DO, FSAHM, FACOFP, DFASAM Timothy Wiegand, MD, FACMT, FAACT, DFASAM

REGIONAL DIRECTORS

Anika, Alvanzo, MD, MS, FACP, DFASAM Gavin Bart, MD, PhD, DFASAM Gregory X. Boehm, MD, DFASAM Murtuza Ghadiali, MD, FASAM Frank James, MD, JD, FASAM Miriam Komaromy, MD, FACP, DFASAM A. Kenison Roy, III, MD, DLFAPA, DFASAM Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM Scott Teitelbaum, MD, DFASAM Melissa Weimer, DO, MCR, FASAM

EX-OFFICIO

Brent Boyett, DO, DMD, DFASAM Joseph M. Garbely, DO, DFASAM Randolph P. Holmes, MD FASAM Ilse Levin, DO Penny S. Mills, MBA, Executive Vice President/CEO Aleksandra Zgierska, MD, PhD, DFASAM

FOUNDING PRESIDENT

Ruth Fox, MD 1895-1989 September 27, 2019

The Honorable Seema Verma Administrator, Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Attention: CMS-1715-P P.O. Box 8016 Baltimore, MD 21244-8016

Re: Medicare Program; CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations

Dear Administrator Verma:

On behalf of the American Society of Addiction Medicine (ASAM), a national medical specialty society representing more than 6,000 physicians and other clinicians who specialize in the prevention and treatment of addiction, thank you for the opportunity to comment on the notice of proposed rulemaking (NPRM) regarding the Medicare Program; CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations.

First, we are pleased that the agency has proposed the creation of two different bundled payment models, one for outpatient treatment of opioid use disorder (OUD) and one for services rendered by opioid treatment programs (OTPs). Updating the reimbursement structure surrounding treatment of substance use disorder (SUD) and OUD is vital to strengthening the addiction treatment workforce and delivering quality, evidence-based care. While the proposed payment bundles are a positive step forward, we propose modifications that we believe will better serve patients and their treatment teams. ASAM believes that CMS should finalize these proposals, but with modifications, especially in the case of the OTP bundle regarding the payment amounts, definitions of covered services, and various other issues. We share our recommendations and concerns in more detail below.

Second, ASAM appreciates the opportunity to provide input on CMS' proposal to permit CMS to revoke or deny Medicare enrollment for physicians and eligible professionals who were the subject of prior action from state oversight entities with underlying facts reflecting improper physician or eligible professional conduct that led to patient harm. Decisions surrounding a physician or eligible professional's ability to practice should be determined by their personal physician and the state's medical licensing board. We encourage CMS not to finalize its new proposal to deny or revoke enrollment for any action a state medical board takes, or, at a minimum, narrow the scope of this exclusion to avoid targeting state-mandated abstinence or substance use disorder treatment. We have provided additional information regarding potential unintended consequences of the proposed policy below.

Thank you for the opportunity to comment on the NPRM regarding the 2020 Medicare Physician Fee Schedule. If you have any questions or need further clarification, please do not hesitate to contact Corey Barton, Senior Manager, Private Sector Relations for ASAM at 301-547-4106.

Sincerely,

Paul H Earley M.D.

Paul H. Earley, MD, DFASAM President, American Society of Addiction Medicine

2020 MPFS Detailed Comments

Table of Contents

A.	Bundl	ed Payment for Treatment of Opioid Use Disorder (OUD)	pg. 4
	a.	Executive Summary	pg. 4
	b.	Accounting for Patient Severity	pg. 4
	с.	Consulting with Addiction Physician Specialists	pg. 5
Β.	Medio	care Coverage for Opioid Use Disorder Treatment Services Fu	urnished by
	Opioi	d Treatment Programs (OTPs)	pg. 5
	a.	Proposed Definition of OUD treatment services	pg. 6
	b.	OTP Enrollment	pg. 7
	с.	Review of Medicaid and TRICARE	pg. 7
	d.	Aspects of the Bundle	pg. 9
	e.	Coding and Payment	pg. 9
	f.	Alternative Proposal Rationale	pg.11
C.	Refer	ences	pg. 14
D.	Apper	ndix A	pg. 15
		ndix B	

Bundled Payment for Treatment of Opioid Use Disorder (OUD)

Executive Summary

In last year's comments to CMS, ASAM reaffirmed that addiction is a chronic brain disease. Payment models and processes for addiction treatment must be designed in a manner that reinforces treatment plans that enable patients to progress through their individualized recovery processes. Increasing access to medications that have been proven to be effective in treating individuals diagnosed with OUD is a critical component. The existing fee-for-service system does not adequately provide the resources that physicians and their treatment teams need to ensure that patients have access to quality, evidence-based addiction treatment. Given these issues with access to care, we are pleased that CMS has responded to these barriers to access by proposing new payment codes in this Notice of Proposed Rule Making (NPRM) that are aimed at facilitating increased access to comprehensive addiction treatment for patients suffering from OUD.

However, ASAM recommends that CMS finalize this proposal with certain refinements. For example, in its proposal, CMS plans to use a building block methodology for the outpatient bundle by cross walking the individual elements of the payment bundle to defined relative value units (RVUs) of similar services defined by existing Current Procedural Technology (CPT) codes. In determining the total relative value units (RVUs) for each code, CMS also makes certain assumptions about the approximate number of individual and group psychotherapy sessions that a patient receives during a calendar month. In the proposed rule itself, CMS recognizes that there is significant patient variability in the need for the services included in the bundle and for future treatments not yet acknowledged. This proposed payment methodology, applying an amalgam of existing CPT codes to estimate a group of services that may be provided by summing the equivalent of the work RVUs referenced from existing CPT codes, needs further refinement. Specifically, ASAM recommends that CMS adjust the payment methodology to account for (1) patient complexity/severity using The ASAM Criteria or other equivalent criteria and (2) different types of practice arrangements and emerging technologies. We also encourage CMS to urge providers to consult addiction physician specialists who have extensive knowledge and expertise, as appropriate, such as when treating patients with moderate to severe OUD.

Accounting for Patient Severity

In our comments to the agency last year, ASAM recommended that CMS consider ASAM and the American Medical Association's (AMA's) joint concept paper (Patient-Centered Opioid Addiction Treatment (P-COAT) Alternative Payment Model). The P-COAT paper recommends a bifurcated payment model that would address patients in two distinct levels of care: outpatient and intensive outpatient. This framework was built on the ASAM Levels of Care which express gradations of intensity of services. It is critically important that patients receive the right level of care, in the right place, and at the right time. We urge CMS to consider using the ASAM Levels of Care, or other equivalent standards, to account for patient severity to ensure that treatment teams have the appropriate resources to address patients' needs. By way of example, at ASAM Level of Care 1.0 (outpatient), patients may need up to 9 hours of services per week to meet their treatment needs. At ASAM Level of Care 2.1 (intensive outpatient), patients typically need more than 9 hours of services per week to meet their treatment needs.

Additionally, the proposed rule identifies an add-on-code, GYYY3 that "can only be billed when the total time spent by the billing professional and the clinical staff furnishing the OUD treatment services described by the base code exceeds double the minimum amount of service time required to bill the base code for the month." This magnitude of provider risk and uncertainty will place a significant burden on providers and their ability to effectively serve their patients. In addition to our recommendation that CMS make certain refinements, ASAM also recommends that within any methodology for valuing these codes, CMS consider a lower threshold for billing this code. *Specifically, CMS should consider lowering the threshold to allow providers to bill the add-on code "when the total time spent by the billing professional and the clinical staff furnishing the OUD treatment services described by the base code exceeds 125-150% of the minimum amount of service time required to bill the base code for the month."*

Consulting with Addiction Physician Specialists

CMS notes that it is not proposing to require consultation with a specialist as a condition of payment for these codes. While primary care physicians are no doubt a critical part of the addiction treatment workforce, addiction psychiatrists, as well as non-psychiatrist physicians certified by ASAM, the American Board of Addiction Medicine (ABAM), the American Osteopathic Association (AOA), and/or the American Board of Preventive Medicine (ABPM) have earned board certifications that designate them as the most trained and experienced specialists available to provide quality treatment to patients diagnosed with OUD. These addiction physician specialists have undergone a rigorous certification process and devote a significant portion of their clinical activity providing treatment to patients with addiction. They are also a critical part of our addiction treatment workforce. Accordingly, we urge CMS to recommend to treatment teams that they consult with addiction physician specialists when encountering patients who have more complex needs involving moderate to severe OUD.

<u>Medicare Coverage for Opioid Use Disorder Treatment Services Furnished by Opioid</u> <u>Treatment Programs (OTPs)</u>

OTPs are an essential component of the addiction treatment ecosystem. According to The ASAM Criteria, "[these programs are comprised of treatment teams] who provide patient-centered and recovery-oriented individualized treatment, case management, and health education... The nature of the services provided, including dose, level of care, length of service, and frequency of visits, is determined by the physician and based on the patient's goals and clinical need."¹ Given the highly regulated nature of OTPs, ASAM is pleased that CMS has proposed a very extensive plan for paying for these treatment services in a manner that does not significantly alter physicians' current practices. ASAM believes this new benefit will be extremely beneficial for Medicare beneficiaries receiving treatment in an OTP, and we are pleased to welcome the end of an era of OTP's being categorical excluded from Medicare coverage. We commend CMS for recognizing the vital role that OTPs have in the addiction treatment ecosystem by proposing a coding and payment structure that recognizes drug and non-drug services; however, there are also portions of the proposal which warrant refinement.

Proposed Definition of OUD treatment services

The SUPPORT Act lists five services that CMS must cover. They include (1) opioid agonist and antagonist medications (oral, injected, and implanted versions), (2) dispensing and administration of the medications, (3) substance use counseling by a professional authorized under state law, (4) individual and group therapy with a physician or psychologist (as authorized by state law), and (5) toxicology testing. Section 2005 also gives the Secretary of HHS the discretion to add other items deemed as appropriate (except for meals and transportation). CMS is proposing to cover all these services plus telecommunications services. CMS notes in its proposal that the agency is interested in public feedback on whether intake activities, which may include services such as an initial physical examination, initial assessments and preparation of a treatment plan, as well as periodic assessments, should be included in the definition of OUD treatment services. We believe they should, because these are significant activities performed by treatment teams that are not currently included in the proposed bundle, nor are they paid for separately in OTPs. Accordingly, we urge CMS to define covered OUD treatment services in OTPs as the following:

- 1. Opioid agonist and antagonist medications (oral, injected, and implanted versions);
- 2. Dispensing and administration of the medications;
- 3. Substance use counseling by a professional authorized under state law;
- 4. Individual and group therapy with a physician or psychologist (as authorized by state law);
- 5. Presumptive toxicology testing;
- 6. Telecommunications services;
- 7. Case management;
- 8. Intake activities, which may include services such as an initial physical examination, initial assessments and preparation of a treatment plan; and
- 9. Periodic assessments.

We urge CMS to use the authority granted by the SUPPORT Act to include these services in the bundled payment and in the proposed definition of OUD treatment services.

OTP Enrollment

We believe that SAMHSA's process for credentialing and overseeing the accreditation of OTPs is sufficient to ensure the health and safety of patients, and we are supportive of the agency's proposal not to propose any additional conditions for OTPs' enrollment in Medicare at this time. However, we have grave concerns about possible unintended consequences of the portion of the proposal that considers mandated substance use disorder treatment or required abstinence and random drug screening as factors in a Medicare enrollment denial or revocation decision. Specifically, the proposed rule permits CMS to revoke or deny Medicare enrollment for physicians and eligible professionals who were the subject of prior action from state oversight entities with underlying facts reflecting improper physician or eligible professional conduct that led to patient harm. Factors that CMS may consider for a decision to deny or revoke enrollment on this ground include the number and type(s) of sanctions or disciplinary actions that have been imposed against the physician or other eligible professional, including actions such as mandatory abstinence and random drug testing or required participation in substance use disorder treatment, among other factors. While ASAM recognizes that patient safety is of the utmost importance, we believe it is the role of state medical boards to protect the health, safety, and welfare of the residents in the state. Furthermore, as proposed, the enrollment provisions may deter practitioners from seeking needed addiction treatment, lest such treatment result in licensing actions that could subsequently threaten their ability to provide care to Medicare patients. ASAM opposes any state or federal rules or regulations which intentionally or unintentionally function as a deterrent in the earlier detection of potentially impairing illness among healthcare and other licensed professionals, thereby potentially placing the public at greater risk. Because denial of enrollment related to required substance use disorder treatment or mandated abstinence and random drug screening would unintentionally function as a deterrent to medical practitioners seeking treatment or disclosing impairment to a state licensing board, increasing the risk to the public, we oppose this provision as written. ASAM encourages CMS not to finalize its new proposal to deny or revoke enrollment for any action a state medical board takes or, at a minimum, narrow the scope of this exclusion to avoid targeting state-mandated abstinence or substance use disorder treatment.

Review of Medicaid and TRICARE

Section 2005 of the SUPPORT Act provides that the HHS Secretary may consult the TRICARE and Medicaid fee schedules for information about how those programs cover methadone and the related wraparound services. CMS notes that the TRICARE program instituted coverage of OTPs in 2016 based on a weekly bundled payment rate that included the cost of the medications and the non-drug components such as counseling, care coordination, and toxicology testing.² CMS also notes that it reviewed state Medicaid reimbursement models for OTPs and found wide variation. However, CMS has proposed in this NPRM to crosswalk the TRICARE rates to the proposed Medicare

payment rates, despite noting significant variation in state Medicaid payment rates. ASAM notes that some state Medicaid programs pay for OTP services at a higher rate than the proposed Medicare rate. We have included examples of different Medicaid fee schedule arrangements in Appendix B. While ASAM agrees that the implementation of TRICARE coverage for OTPs was a positive development for TRICARE beneficiaries with OUD, we are nevertheless concerned that the finalized TRICARE rates cross-walked to Medicare payment for OTPs will not increase access to treatment for Medicare beneficiaries. The finalized TRICARE rates reflect typical market prices paid to OTPs, and unfortunately, do not represent a systematic, methodical calculation of rates for OTPs. *We recommend that CMS consider an alternative framework that is similar to that used to calculate the values of the proposed G-codes for treatment of OUD in outpatient settings.*

The finalization of the TRICARE rates in 2016 was at a time when many state Medicaid programs did not cover methadone and the associated wraparound services. Many patients seeking treatment from OTPs would be required to pay in cash if they had health insurance coverage that did not cover treatment services in an OTP. Therefore, the final rule that finalized TRICARE rates for treatment services in OTPs did so based on industry billing practices that had primarily relied on cash pay or insurance billing practices that adopted payment rates based on what patients could afford to pay. Cash pay (sometimes referred to as a sliding scale) systems are often set up for patients who do not have insurance coverage or have insurance coverage that does not cover the treatment they need. The result is that treatment teams must significantly discount the cost of treatment, so patients have access to care. On the other hand, this economically strains the ability of the treatment team to provide treatment and either forces the provider to limit the number of patients they can see (e.g., through wait lists, temporarily ceasing to see new patients, etc.) or stop seeing patients all together at a time when the opioid overdose epidemic continues to cause significant mortality.³ Hence, we strongly recommend against using the TRICARE program as a benchmark to set payment rates for the new OTP benefit. Should Medicare use TRICARE as a baseline to set OTP payment rates, this would set the market price for other payers whether CMS intends to do so or not. Should private payers and state Medicaid programs adopt similar rates, these rates, as proposed, could significantly impair access to treatment for patients who need it the most. In Appendix A, we offer an alternative framework that we urge CMS to consider.

Additionally, OTPs are strictly regulated and offer a suite of services that define evidence-based care. Using payment rates that are inadequate to cover the cost of care in OTPs could also impede the administration's ability to monitor and control diversion. While medication access and dispensing are tightly regulated in OTPs, the inability of patients to gain access to an OTP due to inadequate payment rates may result in patients seeking treatment in less expensive and structured settings or continue to use harmful substances. The literature states that one of the main reasons that patients divert medications is because they are seeking treatment.⁴ **We recommend that CMS**

finalize rates in a manner than increases access to treatment and limits incentives for diversion.

Aspects of the Bundle

CMS is proposing to define the duration of an episode as a contiguous 7-day period (could start any day of the week) with no global period on the overall maximum number of weeks an OTP can bill for an episode. CMS is also proposing that for an OTP to bill for an episode, patients must receive a majority (51% or more) of the services listed in the patient's treatment plan in the week the episode is billed to Medicare. In cases where the patient receives at least one (1) of the services in their treatment plan, but less than a majority (<51%) over the course of a week, CMS is proposing to allow the OTP to bill for a partial episode. In cases where a beneficiary does not receive a medication for the treatment of OUD during an episode, CMS is proposing to require that OTPs bill the proposed code for a non-drug partial weekly episode. In weeks where an OTP delivers non-drug services (counseling, therapy, toxicology testing), CMS is proposing to allow OTPs bill for a non-drug episode of care. This may occur when patients are being treated with once-monthly injectable buprenorphine or naltrexone. **ASAM supports the proposed duration, requirements to bill, as well as the definition of an episode, and a partial episode and recommends that the definitions of these aspects of the bundle be finalized.**

Additionally, CMS is proposing to define the payment methodology as a bundled payment that consists of the costs of drug and non-drug components. The agency is also proposing an adjustment to the bundled payment rate for additional counseling or therapy services, as well as payment to OTPs to deliver counseling and therapy services via communications technology. *ASAM supports the payment methodology, the add-on payment, as well as payment for telecommunications, and we urge the agency to adopt these proposals.*

Coding and Payment

CMS is proposing to crosswalk the non-drug component of the proposed payment amount to the amount paid by TRICARE, as established by the final rule published in 2016. The 2019 update to that rule lists the payment for the non-drug component at \$100.46 for a full episode per week. When billing for a partial episode, CMS is proposing that OTPs be allowed to bill for half of this amount (\$50.23). CMS notes that this rate was established by TRICARE in the 2016 rulemaking process and is sufficient given the limited time for rulemaking before Medicare coverage of OTPs is effective beginning January 1, 2020. CMS is also proposing to pay a \$10.50 dispensing fee for the dispensing of the oral medication products (methadone and buprenorphine) and a \$16.94 fee for the administration of the injectable products (buprenorphine and naltrexone). Further, CMS has proposed that when the buprenorphine implant, removal, or removal with reinsertion procedure is performed, the codes and payment amounts for performing these services (G0516, G0517, and G0518) are added to the non-drug component of the bundled payment. Finally, CMS has proposed that the non-drug component for the codes describing partial episodes be calculated based on half of the rate for the non-drug services described in the full episodes. The agency also proposed that the intensity add-on code be calculated based on rates set by state Medicaid programs for similar services.

As noted above, OTPs are an essential part of the addiction treatment ecosystem. These programs are strictly regulated for quality and offer a well-defined set of treatment services. Additionally, as new medications have come to market (oral and extendedrelease buprenorphine and naltrexone products), these programs have offered additional therapies for patients who need treatment modalities other than methadone. Furthermore, these treatment centers are crucial for patients who may not otherwise have access to treatment through office-based opioid treatment. As a result, inclusion of provisions in the SUPPORT Act that expanded Medicare coverage to OTPs was an important step for those Medicare beneficiaries who need access to treatment.

However, stigma has had a negative impact on insurance coverage of methadone and the associated wrap-around services. When the TRICARE rule was finalized in 2016, only a little over 30 states covered methadone and wraparound services.⁵ The TRICARE final rule noted that the program determined the rate for the non-drug services by looking at the prevailing market rates for wraparound services. Given that Medicare did not cover OTPs at that time, potential data sources for TRICARE are reduced to the prevailing rates paid by state Medicaid programs, private health insurance programs, federal block grants, or rates paid by patients using cash. As we noted above, the finalization of the TRICARE rates in 2016 was made at a time when many state Medicaid programs, or private insurers did not cover methadone and the associated wraparound services. Patients needing treatment in an OTP would have to pay cash in order to see a treatment provider at many of those facilities due to the absence of insurance coverage. In essence, the proposed rule refers to a market rate that is significantly discounted rate as it is benchmarked on an insurance industry practice rooted in stigma and limited resources. This practice has economically strained the ability of treatment teams to provide evidence-based treatment and may inadvertently limit access to care at a time when the opioid overdose epidemic continues to cause significant mortality.

Furthermore, The ASAM Criteria considers OTPs to be ASAM Level 1.0 outpatient treatment centers. The main differences between an OTP and an OBOT is that OTPs are more strictly regulated programs, must offer certain onsite wraparound services, and are the only clinics where providers can offer methadone for the treatment of OUD. Hence, there is no logical reason for rates for non-drug services performed in an OPT not to be on par with those in an OBOT. However, CMS is not proposing similar values to the non-drug services in these two settings. *While ASAM understands that OTPs, as entities, will be the covered Medicare provider, and thus the services cannot be valued using RVUs as in physician services, we urge CMS to explore a crosswalk of payments for similar codes of*

services as those defined in this bundle. While ASAM supports the CMS proposal to propose 19 new G codes, we strongly encourage modifications to the proposed rates for the non-drug components of these new bundled G codes. Additionally, we urge CMS to clarify whether the code descriptors that describe the provision of naltrexone refer to injectable or oral naltrexone. While ASAM understands the proposal to refer to injectable naltrexone, we urge the agency to clarify.

Specifically, we urge CMS to consider using one of two approaches. Our rationale and the associated approaches are described below and the detailed spreadsheet with calculations is provided in Appendix A.

Alternative Proposal Rationale

In the proposed rule, CMS proposes to include (1) opioid agonist and antagonist medications (oral, injected, and implanted versions); (2) the dispensing and administration of the medications, (3) substance use counseling by a professional authorized under state law, (4) individual and group therapy with a physician or psychologist (as authorized by state law, (5) toxicology testing, and (6) telecommunications services in the weekly bundled payment rate. CMS crosswalks the total value of the proposed G codes in this bundle to the amount paid by TRICARE for these services (\$100.46/week) and notes that they believe this amount to be sufficient given the limited time available to set rates before the January 2020 implementation deadline, and because the TRICARE proposal was available for public comment before it was finalized. The agency also notes that it is accepting comments on whether intake activities, which may include services such as an initial physical examination, initial assessments and preparation of a treatment plan, as well as periodic assessments, should be included in the definition of OUD treatment services. These services are typically performed by a physician, and if included in the bundle, should appropriately reflect the cost of providing these services. Case management and periodic assessments to adjust the treatment plan are services not currently included in the bundle. ASAM believes that they should be included as these are significant activities that CMS has not yet proposed to be covered elsewhere by Medicare for OTPs.

To determine whether or not ASAM believes the proposed non-drug services bundled payment rate adequately compensates the cost of providing treatment to Medicare beneficiaries in an OTP, ASAM staff and physician members first unbundled the bundled payment rate to list each non-drug service (as identified by CMS) separately. ASAM compiled two tables: one to describe the first week of treatment in an OTP, and another to describe subsequent weeks of treatment, akin to the way CMS proposed to define the outpatient bundle. Once the non-drug services were listed separately, ASAM cross-walked these services to a comparable CPT code that similarly described these non-drug services. Using the AMA's RUC database, ASAM used a Microsoft Excel spreadsheet to list (1) code frequency, (2) last RUC evaluation, (3) intra-service time, (4) total time, (5)

work RVU, (6) practice expense, (7) professional liability insurance, and (8) total RVUs for consideration by CMS. ASAM added a row to this table to sum the total RVUs of each individual non-drug service, as well as the sum total time of each individual service.

The total RVUs for each separately listed non-drug service equaled **8.81**. ASAM multiplied the total RVUs (**8.81**) by the 2020 proposed conversion factor of **36.0896** to arrive at **\$382.60**. Given that drug testing services are not a part of the physician fee schedule and thus are calculated separately without RVUs, this figure includes **\$64.65** for presumptive drug testing (CPT 80307). The cost of definitive drug testing warrants their exclusion from the bundle. The same methodology was used to determine payment amounts for these services if they were unbundled and different payment amounts were provided to OTPs in the second and subsequent weeks of treatment. The total RVUs equated to **7.49**. Multiplying these total RVUs by the proposed conversion factor, the non-drug services total to **\$334.96** using this method for the second and subsequent weeks of treatment.

Using the calculations above, if each non-drug service was included in the bundle as proposed by CMS, including those services that ASAM recommend CMS include, the non-drug portion of the bundle would equal **\$382.60** for the first week, and **\$334.96** for the second and subsequent weeks. These figures are substantially higher than the **\$100.46** figure that CMS is proposing to use, thus causing great concern to ASAM that this bundled rate, as proposed, does not adequately capture the cost of providing evidence-based treatment in OTPs.

Using the same methodology that CMS uses to calculate the total per week payment to OTPs (non-drug + drug services), ASAM calculated the total payment amounts under the above scenarios. We did not propose or use an alternative rate for the dispensing/administration or drug costs. We also did not alter the methodology for calculating the rates for partial episodes as proposed by CMS. Our calculations focused solely on whether the rate for the non-drug services reflected rates that would be used if these services were unbundled in traditional outpatient settings. As we have noted earlier in our comments, services offered in OTPs are akin to those offered in traditional ASAM Level 1.0 outpatient settings. The only difference between OTPs and office-based opioid treatment (OBOT) programs is the means of regulation and medication offered. Hence, the different settings should not be cause to pay wholly dissimilar rates. In the end, our calculations reflect rates that are substantial higher than what CMS has proposed and again, raises concerns about whether the proposed rates are adequate. While ASAM understands that the proposed bundle is not technically a physician service and thus not defined using RVUs, we nonetheless are aware that CMS has previously used a building block methodology to crosswalk services to build payment rates. We strongly urge them to consider doing so here, as well.

Alternatively, CMS could use the total time and the total RVUs of ASAM's proposed first week and second/subsequent week bundles to crosswalk the rates of these proposed bundles to an existing CPT code with a similar total time and total RVUs. We believe that either approach would yield significantly different results than what CMS has proposed in this rule.

Additionally, similar to our recommendation above regarding office-based OUD treatment, we urge CMS to ensure that payment amounts in OTPs be risk stratified to reflect patients who need more services or more resource-intensive services. While CMS has recognized that there is a range of service intensity depending on the patient's severity, the agency has not actually proposed any variations in the OTP payment bundles to recognize service intensity. ASAM recommends that CMS use the ASAM Criteria or equivalent framework to account for patient severity. For example, CMS could stratify the payment amounts based on ASAM Level 1.0 and ASAM Level 2.1 services. Similarly, we recommend that CMS consider how its proposed policies could be best applied or modified to address patients transitioning from an OTP setting to an office-based OUD treatment setting, or vice versa. While the services offered in these two settings are similar, the practice arrangements, and regulatory requirements are different.

Other

CMS has also requested feedback on the use of medications for addiction treatment in the emergency department (ED). We note that due to existing barriers to treatment in the outpatient sector, many individuals suffering from opioid addiction first encounter medications and medical treatment in emergency room settings. In fact, research shows that an increasing number of Medicare beneficiaries have been hospitalized in the United States from opioid poisoning.⁶ Hence, it is critically important that medications for the treatment of addiction involving opioid use be made available and accessible to patients who enter the healthcare system through the emergency room. For example, ED practitioners currently licensed by the Drug Enforcement Agency (DEA) can give a patient in an ED a dose of buprenorphine during their ED visit. Research has shown that "among opioid-dependent patients presenting for emergency care, ED-initiated buprenorphine, compared with brief intervention and referral, significantly increased engagement in formal addiction treatment, reduced self-reported illicit opioid use, and decreased use of inpatient addiction treatment services."⁷ The same practitioner of their colleagues may give follow-up dosing on the subsequent two days. At this critical juncture, it is imperative that the treating practitioner link patients to care in outpatient settings to ensure they continue to have access to treatment. However, given the limited availability of addiction medicine specialists, the availability of practitioners providing the patient's treatment regimen as identified in their treatment plan, insurance restrictions, as well as other socioeconomic factors, not all patients are successfully linked to a practitioner for continuous treatment. As a result, some patients may relapse or even die. Therefore, ASAM supports efforts by CMS and others to develop coding and reimbursement strategies that support emergency physicians in providing this complex and critical care in the ED-settings.

ASAM has also heard concerns from members regarding the restrictive coverage implications if only doctoral-level practitioners are eligible to bill Medicare for counseling/therapy services that are rendered. Many providers that deliver these services only have masters-level education. We encourage CMS to ensure that billing requirements for those services proposed under this section do not inadvertently inhibit access to treatment by requiring professional qualifications that do not match the current available workforce capacity.

¹ Mee-Lee, D., Shulman, G., Fishman, M., Gastfriend, D., Miller, M., Provence, S. (2013). *The ASAM Criteria* (3rd ed). Chevy Chase, MD: ASAM Publications Department.

² 32 CFR § 199 2016.

³ Substance Abuse and Mental Health Services Administration. (2019). *Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health* (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality.

⁴ Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. *Journal of addiction medicine*, 8(5), 315–326. doi:10.1097/ADM.000000000000045

⁵ Rinaldo, S., Rinaldo, D. (2013). Advancing Access to Addiction Medications. San Francisco, CA: The Avisa Group.

⁶ Song, Z. (2017). Mortality quadrupled among opioid-driven hospitalizations, notably within lower-income and disabled white populations. Health Affairs, 36(12), 2054-2061.

⁷ D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., ... & Fiellin, D. A. (2015). Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. Jama, 313(16), 1636-1644.

Appendix A

International Control Contro Contro Control Control Control Control Control Control Control C	First week of treatment in an OTP											
and of the spectra o		Crosswalk Code		Code Frequency	Last RUC Evaluation	Intraservice Time (mins)	Total time (mins)	Work RVU	Practice Expense	PLI	Total RVUs	Other Payment
Interfactor				10,381,133	2019	40	60					
International products controls of all												
Notice of the												
Interview Interview <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
Inter range Inter of the property and/or band/range Inter of the property and/or band/range <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>												
Initial in generating point in a finance of the space of the spac												
Instrume Instrum Instrum Instrum In												
Initiation 9905 (spin). Initiation Initi												
Or Many energy in the set of the	Initial intake	99204						2.6	1.00	0.21	4.8	
Balance of their apprictance, strateging spectra on the properture of the strateging spectra on the strateging spectr	initial intake	55204		21 201	2017	30	30	2.0	1.55	0.21	4.0	
Scientific balance presenting presenting registering the present solution of the section of the sectin of the section of the section of the section of the				21,201	2017	50	50					
Advance secure 4 metrics into a secure 4 metric												
Instance												
Image with the stand and provide and an analysis of the stand and analysis of the stand analysis of the stand and analysis of the stand and ana												
Antipuestion Antipuestin antipuestion Antipuestion <td></td>												
Care Nageson Instant also as public formation and a												
one hadre propositie constitution, indication, of one with a construction, indication, and construction, andinterest and construction, andiant construction, and co			progressing or whose status changes; facilitating and coordinating									
Care Management Other Management O Imagement												
Care Management Other Management O Imagement												
Goog Nergy 0.000 (org. procentry equipation from the analyse hange grant 97.48 2002 00 01 0.00 0.00 Series Processes												
Dec total percentagive, sympather of galaxies, sympather disconce of peopletics, function of the section of the sectio	Individual Therapy											
Image: section of a construct is produced registering multiple sides and produced registering multiple	Group Therapy	90853				60	95	0.59	0.15	0.02	0.76	
Image: section of the sectin of the section of the section				3,068,671	N/A							
Impaint in the processing in the processing of the processing is provide using on the processing is provide using in the processing is processing in the processing is provide using in the processing is p												
phonomic program call bit with a characterization (c.e., DAR, SCH, MAD, C.G.) control of program con												
manuplex fung screening MS, LK M(N), DDN, DDN, DDN, DDN, DDN, DDN, DDN, D												
Presentation Objectering 60000 performant condition Control Contro Contro Contro												
Total Image: Constraint of the section of the sectin of the sectin of the section of the section of the section of t											_	
Conversion lataria 38.0000 38.0000 Conversion lataria Conversion		80307	performed, per date of service			100	225	5.2	2.10	0.22	0	\$ 64.65
Barbon Barbon<		36.0906				100	235	5.3	5.19	0.32	10.0	
Source AMA BUC Database Control Contro Control Control<	conversion factor											
Service Crisival Code Crisival Code Consumal Code Description Code Prequeers Last RUC Pollution Intraservice Time (minit) Total time (minit) Practice Expense PU Total Pollution Service Crisival Code Orsswal Code Orsswal Code Prequeers 103.379.568 2019 30 102 12.48 Plant 104.87 Plant 104.87 Plant 104.87 Plant 104.87 Plant 104.87 Plant	Source: AMA RUC Database	302.333370										
Service Conswelk Code Conswelk Code Code Respensely (and particular Visit for equations) with requires at least 2 of three 3 key components. A classical bit my challed examination, reducting and/or constraint or a netabilished patient, with requires at least 2 of three 3 key constraints, cher qualified health exclusion making of moderate complexity. Constraint of an estabilished patient, with requires at least 2 of three 3 key constraints, cher qualified health exclusion making of moderate complexity. Constraint of an estabilished patient, with requires at least 2 of three 3 key constraints of a weith the physich qualified health exclusion making of moderate complexity. Constraints of the patient and/or transfer of the problem) and the patient and/or transfer quality. The problem is problem is physich transfer of the problem is physich tran	Source: Autorite Batabase											
Service Costavalk Code Dotavalk Code Decayable Code Last RUC Evaluation Intraservice Time (Imit) Total Imite (Imit) Volt RUC Parameter Parameter Total Imite (Imit) <	Second and subsequent weeks of treat	tment in an OTP										
offer or other outpatient with offer the evaluation and management of an establic patient, which requires a last 2 diverse last 2 components. A detailed batter, which requires a last 2 diverse last 2 constraints of an establic patient, which requires last 2 diverse last 2 constraints of ance with hole physican, other physican, other qualified batts are professionally a regione are profession physican of the physican profession 2 minutes are gent the physican of the physican of the physical is a second are with the physican of the physican of the physical is a second are with the physican of the physican of the physical is a second are with the physican of the physican of the physical is a second are with the physican of the physican of the physical is a second are with the physican of the physican of the physical is a second are with the physican of the physical is a second are with the physican of the physical is a second are of the physican of the physical is a second are with the physican of the physical is a second are physican of the physican of the physican of the ph			Crosswalk Code Description	Code Frequency	Last RUC Evaluation	Intraservice Time (mins)	Total time (mins)	Work RVU	Practice Expense	PLI	Total RVUs	Other Payment
Periodic assessments omponents:: detailed history: A detailed semination, Medial accommany of model consistent with the state of the problem (s). Consensing and/or motify's needs, build, and the patient state of the problem (s) and the patient state of the problem (s) and the state of			Office or other outpatient visit for the evaluation and management	103,974,565	2019	30	49	1.92	1.46	0.1	3.48	
Periodic assessments escion making of moderate complexity. Counseling and/or coordination of car with the problem); and or projective and the problem); and in product as to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem(s) are of moderate to bigh security. Usually, the presenting problem (security are of moderate to bigh security. Usually, the presenting problem (security) are of moderate to bigh security. Usually, the presenting problem (security) are of moderate to bigh security. Usually, the presenting problem (security) are of the problem); and or moderate to bigh security. Usually, the presenting problem (security) are of the problem); and or moderate to bigh security. Distribution of the security of the transmitter of the problem (security) are of the problem); and or moderate to bigh security. Usually, the presenting including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to behavioral health conditions; at least to antioner, including relation to antipied of the crite with a social approprint (as constructioner); anothan assented to anothan assented tor follow approprinte and (as												
Periodic assessments occontinuation of care with other physicians, other qualified health care projectionals, or generated to high secretion. Secretion Secretion </td <td></td> <td></td> <td>components: A detailed history; A detailed examination; Medical</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			components: A detailed history; A detailed examination; Medical									
are professional, or genotes are provided constant with the patients and/or family's needs. Usually, the presenting problem(s) are of moderate to high seventy. Typically, 25 minutes are genotes to act to far awate problem (s) are of moderate to high seventy. Typically, 25 minutes are setting roblem(s) are of moderate to high seventy. Typically, 25 minutes are setting roblem(s) are of moderate to high seventy. Typically, 25 minutes are setting roblem(s) are of moderate to high seventy. Typically, 25 minutes are setting roblem(s) are of moderate to high seventy. Typically, 25 minutes are setting roblem(s) are of moderate to high seventy. Typically, 26 minutes of financial staff time, directed by aphycican or other qualified heats care professional, per calculating the directed to aphycically addited rate galance and are planning in relation to behavioral postheration to enhavioral postheration to												
Periodic assessments nature of the problem(s) and the patient synder to high sends. Subj. the presenting portantes to high sends. nature of the problem(s) and the patient and/or spressments nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the patient to high sends. nature of the patient to high sends. nature of the problem(s) and the patient to high sends. nature of the patient to high sends.												
Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes sequents conditions, at least severity. Typically, 25 minutes sequents conditions, at least 21,201 Can be assumed to the problem (s) and the problem												
Pendidic assessments Typically, 25 minutes are spent face-to-face with the patient and/or analy. Care management services for behavioral health conditions, at least a continues of linicit set linicit, assessment or follow-up monitoring, including the use of applicable validited ring scales; be baavioral health care patients intel assessment or follow-up monitoring, including the use of applicable validited ring scales; be baavioral health care patients in that assessment or follow-up monitoring, including the use of applicable validited range scales; be baavioral health care patients in that assessment or follow-up monitoring, including retuined demonstrating acales; be baavioral health care patients in that assessment or follow-up monitoring, including retuined demonstrating scales; be baavioral health care patients what are not progressing or whore scalues chares; for failaring and continuity of care with a progressing or whore scalues chares; for failaring and continuity of care with a midividual therapy. Sector Management patient scalues chares; for failaring and continuity of care with a progressing or whore scalues chares; for failaring and continuity of care with a progressing or whore scalues chares; for failaring and continuity of care with a progressing or whore scalues chares; for failaring and continuity of care with a progressing or whore scalues chares; for failaring and continuity of care with a progressing whore scalues chares; for failaring and continuity of care with a progressing whore scalues chares; for failaring and continuity of care with a progressing whore scalues chares; for failaring and continuity of care with a progressing whore scalues chares; for failaring and continuity of care with a progressing whore scalues chares; for failaring and continuity of care with a progressing whore scalues chares; for failaring and continuity of care with a protent perophotence protechares; for failaring and continuity of ca												
Periodic assessments 09214 family, come management services for behavioral health conditions, at least 21,201 2011 30 Image: Come management services for behavioral health conditions, at least 21,201 2011 30 Image: Come management services for behavioral health conditions, at least 21,201 2011 30 Image: Come management services for behavioral health conditions, at least 21,201 2011 30 Image: Come management services for behavioral health conditions, at least 21,201 2011 30 Image: Come management services for behavioral health conditions, at least 21,201 2011 30 Image: Come management services for behavioral health conditions, at least problems, including teusion for patients who are not progressing or whose stuts changes; ficture at an other progressing or whose stuts changes; ficture at another progressing or whose stuts changes; ficture at another progressing or whose stuts changes; for populating for agressing and coordinating treatement suck as psychotherapy, management 20444 2012 30 50 10.5 10.3 10.5												
Care management services for behavioral health care professional, per calendar month, with the gualified health care professional, per calendar north, with the following required retements: initial sessment or follow-up monitoring, including the use of applicable voltation to behavioral health care planning in relation to behavioral health progressing or whose status charges, facilitating and coordinating progressing or whose status charges, facilitating and continuity of care with a new than a superchaintic consultation, and continuity of care with a new the new theorem the status as psychotherapy, tharmacotherapy, counseling and/or psychaitric consultation, and continuity of care with a new the new theorem the status as psychotherapy, tharmacotherapy, counseling indulty psychaitric consultation, and continuity of care with a new the new theorem the new theorem the status as psychotherapy, tharmacotherapy, counseling and/or psychaitric consultation, and continuity of care with a new the new theorem the new the new theorem the	Desiedia											
20 ninutes of linical saff time, directed by a physician or other qualified health care phoresional, per calendar month, with the following required elements: initial assessment of follow-up monitoring. Including the used applicable validated rating sales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision of patients who are not monotrong. Including the used applicable validated rating sales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision of patients who are not monotrong. Including crevision of crevisites and monotrong monotrong. Including crevision of crevisites and monotrong monotrong. Including crevision of crevisites and crevisites and crevisitiang and coordinating treatments who are not monotrong. Including crevisites any and press for any crevisites and crevisites anding crevisites and crevisites and crevisites	Periodic assessments	99214										
care Management 9944 designated many with the tase of applicable valuation to behavioral psychiatric and coordinating and coordina				21.201	2017	- 20						
care Management 99484 designated member of the care team. 0.61 0.7 0.04 1.35 care Management 99484 designated member of the care team. 0.61 0.7 0.00 1.35 care Management 99484 designated member of the care team. 0.61 0.7 0.00 1.35 care Management 99484 designated member of the care team. 0.61 0.7 0.00 1.35 care Management 99484 designated member of the care team. 0.61 0.7 0.00 1.35 concy Therapy 99082 Psychotherapy, 00minutes with patient 2.341.422 2012 30 50 50.5 0.02 0.6 0.7 0.00 1.35 Group Therapy 90832 Psychotherapy, 04 minutes, any number of ding classes, any number of ding class				21,201	2017	30	30					
and/or psychiatric consultation; and cutoring in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; failuting and coordinating treatment who as psychiotherapy, harmacotherapy, tourseling and/or psychiatric consultation; and cutorinating treatment who are not progressing or whose status changes; failuting and coordinating treatment who are possible and the progressing or whose status changes; failuting and coordinating treatment who are possible and the progressing or whose status changes; failuting and coordinating treatment who are not progressing or whose status changes; failuting and coordinating treatment with psychiatric consultation; and continuity of care with a and/or psychiatric consultation; and containing treatment with patient 2.341.482 2012 30 50 1.5 0.03 0.05 1.9 Group Therapy 90832 Group psychotherapy (other than of a multiple family group) 977.488 2012 60 95 0.05 0.02 0.07 Group Therapy Drug test(s), presumptive, any number of dug classes, any number of devices or procedure; by instrument femily transpress (e.g., utilizing immanessay (e.g., GK, SG, GC, SK, SK, SK, C, MS, SL, CMS, SK, SK, SK, SK, SK, SK, SK, SK, SK, S			20 minutes of clinical staff time, directed by a physician or other	21,201	2017	30	30					
behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, nounseling and/or psychiatric consultation; and continuity of care with a individual Therapy especial consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a individual Therapy especial consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a individual Therapy especial consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a individual Therapy especial consultation; and continuity of especial consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a individual Therapy especial consultation; and continuity of especial consultation; and untiple-family group) especial consultation; and untiple-family group; and unti			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the	21,201	2017	30	30					
care Management 9948 designated member of the care team. e 0.01 0.01 0.02 0.05 1.35 care Management 9948 designated member of the care team. 0.01 0.03 0.05 0.05 0.05 0.05 0.05 0.076 individual Therapy 99633 designated member of the care team. 0.01 0.05 0.05 0.05 0.05 0.05 0.05 0.076			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up	21,201	2017	30	30					
and progressing or whose status charge, facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a and progressing or whose status charge, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a and progressing or whose status charge, pharmacotherapy, pharmacotherapy, pharmacotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a and progressing or whose status charge, pharmacotherapy, pharmacother			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales;	21,201	2017	30	30					
Care Management 9944 designated member of the care team. 0.01 0.01 0.00 1.35 Individual Therapy 99033 Psychotherapy, 30 minutes with patient 2,341,482 2012 30 50 1.5 0.0.5 0.0.5 0.0.7 0.0.4 1.35 Group Therapy 99033 Psychotherapy, 30 minutes with patient 2,341,482 2012 30 50 5.5 0.05 0.07 0.04 1.35 Group Therapy 99033 Psychotherapy, 10 dimutes with patient 2,341,482 2012 30 50 5.5 0.05 0.07 0.04 1.35 Group Therapy Drug test(s), presumptive, any number of drug classes, any numb			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric	21,201	2017	30	30					
and/or psychiatric consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a and/or psychiatric consultation; and continuity of care with a and/or psychiatric consultation; and/or psychiatric consychiatric consultation; and/or psychiatric			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not	21,201	2017	30	30					
Care Management 99484 designated member of the care team. 0 0 0.61 0.7 0.04 1.35 Individual Therapy 90832 Psychotherapy, 30 minutes with patient 2,341,82 2012 30 50 0.15 0.05 </td <td></td> <td></td> <td>20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating</td> <td>21,201</td> <td>2017</td> <td>30</td> <td>30</td> <td></td> <td></td> <td></td> <td></td> <td></td>			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating	21,201	2017	30	30					
Individual Therapy 99032 Psychotherapy, 30 minutes with patient 2,341,422 2012 30 50 1.5 0.05 1.9 Group Therapy 99083 Group psychotherapy (30 minutes with patient) 977,488 2012 60 95 0.05 0.05 0.02 0.07 Drug text[s], presumptive, any number of drug classes, any			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/spx/chaitric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plarmacotherapy, counseling	21,201	2017	30	30					
Group Dependence of y psychother apy (other than of a multiple-family group) 977.488 2012 60 95 0.059 0.15 0.02 0.76 Drug test(s), presumptive, any number of drug classes, any numbe	Care Management	99484	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a	21,201	2017	30	30	0.61	0.7	0.04	1.35	
Presumptive Drug Stetisle, presumptive, any number of drug Classes, any number 3,068,671 N/A Image: Step Step Step Step Step Step Step Step			20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated trating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team.						•			
vilizing immunoassay (e.g., IK, LUSA, EMIT, FPA, A, KINS, RA)), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC MS, LC-MS/MS, LDTD, MALD), TOF) includes sample validation when Presumptive Drug Screening a	Individual Therapy	90832	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, planmaconterapy, courseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy. 30 minutes with patient	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS/MS, LC- MS, LC-MS/MS, LDT, MALD), TOF) includes sample validation when Presumptive Drug Screening no n	Individual Therapy	90832	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group)	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
Presumptive Drug Screening Or without chromatography, (eg., DART, DESI, GC-MS/MS, LC-MS/MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when Annotation Annonation	Individual Therapy	90832	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plarmacoherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, Other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g.,	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
MS, LC-MS/MS, LDTD, MALDi, TOF) includes sample validation when MS LC-MS/MS, LDTD, MALDi, TOF) includes sample validation when MS LC-MS/MS, LDTD, MALDi, TOF) includes sample validation when MS LC-MS/MS, LDTD, MALDi, TOF) includes sample validation when MS	Individual Therapy	90832	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated trating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immonassay (e.g., ELA, ELSA, EMT, PFA, IA, KIMS, RIA)],	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
Presumptive Drug Screening 80007 performed, per date of service 0	Individual Therapy	90832	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, planmacoherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., EIA, EUSA, EMIT, FPIA, IA, KIMS, RIA)), chromatography (e.g., GL, HPLC), and mass spectrometry either with ther with	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
Total Image: Conversion factor Signature	Individual Therapy	90832	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plarmacoherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., ELA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DES), GC-MS, GC-MS/MS, LC	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
Conversion factor 36.0896 <	Individual Therapy Group Therapy	90832 90853	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plasmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., CHPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when	2,341,482 977,488	2012 2012	30	50	1.5	0.35	0.05	1.9	
334,96104	Individual Therapy Group Therapy Presumptive Drug Screening	90832 90853	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plasmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., CHPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when	2,341,482 977,488	2012 2012	30 60	50 95	1.5 0.59	0.35 0.15	0.05	1.9 0.76	\$ 64.65
	Individual Therapy Group Therapy Presumptive Drug Screening Total	90832 90853 80307	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plasmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., CHPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when	2,341,482 977,488	2012 2012	30 60	50 95	1.5 0.59	0.35 0.15	0.05	1.9 0.76	\$ 64.65
Suirce AinA Ruc Dulutuse	Individual Therapy Group Therapy Presumptive Drug Screening Total	90832 90853 80307 36.0896 36.0896	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plasmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., CHPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when	2,341,482 977,488	2012 2012	30 60	50 95	1.5 0.59	0.35 0.15	0.05	1.9 0.76	\$ 64.65
	Individual Therapy Group Therapy Presumptive Drug Screening Total Conversion factor	90832 90853 80307 36.0896 36.0896	20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, plasmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team. Psychotherapy, 30 minutes with patient Group psychotherapy (other than of a multiple-family group) Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., CHPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when	2,341,482 977,488	2012 2012	30 60	50 95	1.5 0.59	0.35 0.15	0.05	1.9 0.76	\$ 64.65

OTP Code Descriptors and Proposed A	pproximate Payment Amounts for	first week of treatment in an OTP					
HCPCS	Descriptor	Drug Cost	Non-drug Cost	Dispensing/Administration Costs	Total Alternative Payment	CMS Proposed rate	Difference
Full weeks							

TBD								
	Medication assisted treatment,	\$22.19	\$382.60	\$10.50	\$415.29	\$	133.15	
	methadone; weekly bundle							
	including dispensing and/or							
	administration, substance use							
	counseling, individual and group							
	therapy, and toxicology testing, if							
	performed (provision of the							
	services by a Medicare-enrolled							
	Opioid Treatment Program)							212%
TBD	Medication assisted treatment,	\$97.02	\$382.60	\$10.50	\$490.12	\$	207.98	
	buprenorphine (oral); weekly					· ·		
	bundle including dispensing							
	and/or administration, substance							
	use counseling, individual and							
	group therapy, and toxicology							
	testing if performed (provision of							
	the services by a Medicare-							
	enrolled Opioid Treatment							
	Program)							136%
TBD	Medication assisted treatment,	\$1,580.00	\$382.60	\$16.94	\$1,979.54	\$ 1	1,697.40	
166		\$1,500.00	5562.00	\$10.54	\$1,575.54	Ŷ	1,037.40	
	buprenorphine (injectable);							
	weekly bundle including							
	dispensing and/or							
	administration, substance use							
	counseling, individual and group							
	therapy, and toxicology testing if							
	performed (provision of the							
	services by a Medicare-enrolled							
								17%
	Opioid Treatment Program)							1/%
TBD	Medication assisted treatment,	\$4,792.10	\$382.60	245.79*	\$5,174.70	\$	5,003.56	
	buprenorphine (implant							
	insertion); weekly bundle							
	including dispensing and/or							
	administration, substance use							
	counseling, individual and group							
	therapy, and toxicology testing if							
	performed (provision of the							
	services by a Medicare-enrolled							
	Opioid Treatment Program)							3%
TBD	Medication assisted treatment,	\$0	\$382.60	265.25*	\$382.60	S	227.32	
	buprenorphine (implant		-					
	removal); weekly bundle							
	including dispensing and/or							
	including dispensing and/or administration, substance use							
	including dispensing and/or administration, substance use counseling, individual and group							
	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if							
	including dispensing and/or administration, substance use counseling, individual and group							
	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the							
	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled							68%
тво	including dispensing and/or administration, substance use counseiling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Oploid Treatment Program)	\$4.792.10	\$382.60	463.45*	\$5.174.70	5	5.097.26	68%
TBD	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment,	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
TBD	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (Implant insertion and removal); weekly bundle	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
тво	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
тво	including dispensing and/or administration, substance use counselling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
ТВО	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
тво	including dispensing and/or administration, substance use counselling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use	\$4,792.10	\$382.60	463.46* 	\$5,174.70	\$ 5	5,097.26	68%
TBD	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
тво	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicatro-enrolled Opioidi Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ <u></u>	5,097.26	68%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	68%
тво	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicatro-enrolled Opioidi Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the	\$4,792.10	\$382.60	463.46*	\$5,174.70	\$ 5	5,097.26	
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)							68%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment,	\$4,792.10 \$1,164.38	\$382.60 \$382.60	463.46* \$16.94	\$5,174.70 \$1,563.92		5,097.26	
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nattrexone; weekly bundle							
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or							
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nattrexone; weekly bundle							
	including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use							
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, natrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group							
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counselling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counselling, individual and group therapy, and toxicology testing if							
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nattrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the							
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provison of the services by a Medicare-enrolled							2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, natrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)		\$382.60	\$16.94	\$1,563.92		1,281.78	
	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, Medication assisted treatment, Medication assisted treatment,							2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, natrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, meekly bundle not including the		\$382.60	\$16.94	\$1,563.92		1,281.78	2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal), weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, Medication assisted treatment, Medication assisted treatment,		\$382.60	\$16.94	\$1,563.92		1,281.78	2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, natrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, meekly bundle not including the		\$382.60	\$16.94	\$1,563.92		1,281.78	2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, weekly bundle not including the drug, including autoidual and group		\$382.60	\$16.94	\$1,563.92		1,281.78	2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (Implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nattrexone, weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nassisted treatment, exekly bundle on including the drug, including substance use counseling, individual and group therapy, and toxicology testing if berapy.		\$382.60	\$16.94	\$1,563.92		1,281.78	2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, natrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the		\$382.60	\$16.94	\$1,563.92		1,281.78	2%
ТВО	Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, buprenorphine (Implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nattrexone, weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Medication assisted treatment, nassisted treatment, exekly bundle on including the drug, including substance use counseling, individual and group therapy, and toxicology testing if berapy.		\$382.60	\$16.94	\$1,563.92		1,281.78	2%

TBD	Medication assisted treatment,	-	\$382.60	\$0.00	\$382.60	ş -	
	medication not otherwise						
	specified; weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing, if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program)						#DIV/0!
Partial Episodes							#DIV/0!
TBD	Medication assisted treatment,	\$11.10	\$191.30	\$0.00	\$202.39	\$ 66.58	
	methadone; weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX1.						204%
TBD	Medication assisted treatment,	\$48.51	\$191.30	\$0.00	\$239.81	\$ 103.99	
	buprenorphine (oral); weekly						
	bundle including dispensing						
	and/or administration, substance						
	use counseling, individual and						
	group therapy, and toxicology						
	testing if performed (provision of						
	the services by a Medicare-						
	enrolled Opioid Treatment						
	Program); partial episode. Do not						
	report with GXXX2.						
							131%
TBD	Medication assisted treatment,	\$1,580.00	\$191.30	\$16.94	\$1,788.24	\$ 1,647.17	
	buprenorphine (injectable);					-,	
	weekly bundle including						
	dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX3.						9%
TBD	Medication assisted treatment,	\$4,792.10	\$191.30	245.79*	\$4,983.40	\$4,953.33*	
	buprenorphine (implant						
	insertion); weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	another entropy of the test of the test of						
	partial episode (only to be billed						
	once every 6 months). Do not						
700	once every 6 months). Do not report with GXXX4.	60.	(101 20	255.25*	A101.00	A4 77	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment,	\$0	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant	50	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle	\$0 	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant	\$0 	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle	\$0 	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TED	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use	\$0	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group	50	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXXd. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if	\$0	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the	50	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled	\$0	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once very 6 months). Do not report with GXXXd. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program);	50	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!
TBD	once every 6 months). Do not report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled	\$0 	\$191.30	265.25*	\$191.30	\$177.09*	#VALUE!

TBD	Medication assisted treatment,	\$4,792.10	\$191.30	463.46*	\$4,983.40	\$5,047.03*	
	buprenorphine (implant insertion						
	and removal); weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX6.						
							#VALUE!
TBD		\$1,164.38	\$191.30	\$16.94	\$1,372.62	\$1,231.55*	
	naltrexone; weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX7.						#VALUE!
TBD		\$0	\$191.30	\$0.00	\$191.30	\$ 50.23	
	weekly bundle not including the						
	drug, including substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						2040/
TBD	with GXXX8. Medication assisted treatment,						281%
IBD			-	-			
	medication not otherwise specified; weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing, if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX9.						#DIV/0!
Intensity Add-on code			Medication assisted treatment, bup	\$0.00			#DIV/0!
TBD	Each additional 30 minutes of	\$0	-	-		\$ 26.60	
	counseling or therapy in a week						
	of medication assisted treatment,						
	(provision of the services by a						
	Medicare-enrolled Opioid						
	Treatment Program); List						
	separately in addition to code for						
	primary procedure.						-100%

OTP Code Descriptors	and Proposed Approximate Payment Amounts for	second and subsequent weeks of treatment in an OTP					
HCPCS	Descriptor	Drug Cost	Non-drug Cost	Dispensing/Administration Costs	Total Alternative Payment	CMS Proposed rate	Difference
Full weeks							
TBD	Medication assisted treatment,	\$22.19	\$334.96	\$10.50	\$367.65	\$ 133.15	
	methadone; weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing, if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program)						176%
TBD	Medication assisted treatment,	\$97.02	\$334.96	\$10.50	\$442.48	\$ 207.98	
	buprenorphine (oral); weekly						
	bundle including dispensing						
	and/or administration, substance						
	use counseling, individual and						
	group therapy, and toxicology						
	testing if performed (provision of						
	the services by a Medicare-						
	enrolled Opioid Treatment						
	Program)						113%

TBD Medication substant tensment, heterophice lipetication, constrained of point discontegeed of the constrained of point (het ary, indication, substant end constrained figures) SSS.000 SSA 96 SSA 54 SLS1.30 SL 597.40 TBD Medication substant end constrained figures) SA 575 SL 575
weeky bundle notiding definition to the envices by a Medicar environment therapy and boxed by testing a service by a Medicar environment operation of the envices by a Medicar environment operation of the envices by a Medicar environment operation of the envices by a Medicar environment operation of the environment environment operation of the environment environment operation of the environment environment operation of the environment environment operation environment operation environment operation environment
Image:
Image: Section of the section of th
Image: Second
Longening Longening <thlink< th=""> Link <thlink< th=""> Link Link</thlink<></thlink<>
Harapy, and social/og statisting scheme (provision of the christics by a Medican-entrolled biogramme (provision of the christics by a Medican-entrolled biogramme) \$1,22.0
Image: series of instants Same series Same series TBD Medication assisted resummed series of instants Same series TBD Medication assisted resummed series Same series TBD </td
Indexevides by additional ending indication assisted treatment, performed (proceeding additional and group indicating dispersing and/or indicating dispersing and/or indication assisted treatment, operational and group indication assisted reatment, operational and group indicational and group<
Image: Control Testing transmit Space Testing
IBD Medication assisted treatment, instration, weekly bundle restriction, weekly bundle approximation and on the performed (provision of the performed (
bupercorpline (implant including dispersion gend/or administration, subtance including dispersion gend/or administration, subtance terms by Medicate analytic sub- person gend/or administration, subtance true including dispersion gend/or administration,
Institution, institution, subtrance use consisting, instidual and group theragy, and tooology tsting if partners by a backcare-enrolled polymerorphic (implant institution, subtrance use consisting, instidual and group theragy, and tooology tsting if partners by a backcare-enrolled option transmit structure, use consisting, instidual and group theragy, and tooology tsting if performed (noviem) and or administration, subtrance use consisting, instidual and group theragy, and tooology tsting if performed (noviem) and or administration, subtrance use consisting, instidual and group theragy, and tooology tsting if performed (noviem) and or administration, subtrance use consisting, instidual and group theragy, and tooology tsting if performed (noviem) and or administration, subtrance use consisting, instidual and group theragy, and tooology tsting if performed (noviem) and or administration, subtrance use consisting, instidual and group
Including dispensing and/or administration, ubstance us counseling, including dispensing and/or administration ubstance us counseling, including dispensing and/or administration, ubstance us counseling, including dispensing and/or administration, ubstance us counseling, including administration, ubstance us counseling, including dispensing and/or administration, ubstance us counseling, including administration, ubstance us coun
administration, substance use conscienting, individual and group therapy, and toxicology testing if deficient provision of the activice by a Medicare-enrolled object Transmert Argonard instruction assisted treatment, toxicolity and group instruction assisted treatment, toxicolity and group instruction and group and instruction and group and toxicolity and group and instruction and group and instruction and group and instruction and group and instruction and group and offer instruction and group and offer instruct
experiment reperformed (provision of the generation of the generation of the generation assisted restingent, option treatment, Negram)S0S334.96S55.25*S334.96SS27.32TBDMedication assisted restingent, option treatment, Negram)A/92.10S334.96S334.96S5.25*S5.127.06SS5.127.06SSS </td
therapy, and toxicology testing if performed (provision of the services by Medicare-enrolled Opiod Treatment Program)SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96SolSal4.96Sol<
performed (provision of the provises by Adeciace-encolled Opiod Treatment ProgramSO<
services by a Medicare-enrolled poind Treatment ProgramImage: Constraint of the program
LetterOpioid Treatment ProgramImage: Constraint of the sector sect
TBDMedication assisted treatment, bupenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicate-enrolled opioid Treatment Program)5/322.10\$334.96\$5,327.86\$1,227.32TBDMedication assisted treatment, services by a Medicate-enrolled opioid Treatment Program)\$4/32.10\$334.96\$6.346°\$5,127.06\$5,507.26TBDMedication assisted treatment, services by a Medicate-enrolled opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$\$1,281.78TBDMedication assisted treatment, services by a Medicate-enrolled opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicate-enrolled opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$\$1,281.78TBDMedication assisted treatment including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicate-enrolled opioid Treatment Program)\$1,164.38\$334.96\$1,00.48\$1,281.78TBDMedication assisted treatment including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if per
TBDMedication assisted treatment, performed [rowision of the services by a Medication assisted treatment, performed [rowision of the services by a Medicate-service]S0S334.96S25.25*S334.96SS27.32TBDMedication assisted treatment, performed [rowision of the services by a Medicate-service]S4.792.10S334.96S334.96S5.127.06SSS.077.26TBDMedication assisted treatment, performed [rowision of the services by a Medicate-service]S4.792.10S334.96S334.96S5.127.06SS.077.26TBDMedication assisted treatment, performed [rowision of the services by a Medicate-service]S1.16.38SS.077.26TBDMedication assisted treatment, performed [rowision of the services by a Medicate-service]S1.16.38SS.000S1.516.28SS.077.26TBDMedication assisted treatment, nucleaning dispersing and/or administration, subtance use counseling individual and group therapy, and toxicology testing if performed [rowision of the services by a Medicate-service]S1.16.38S1.516.28S1.516.28S1.516.28S1.281.78TBDMedication assisted treatment, individual and group therapy, and toxicology testing if performed [rowising and/or services by a Medicate-service]S1.516.28S1.281.78S1.281.78TBDMedication assisted treatment, individual and group therapy, and toxicology testing if performed [rowising and/or weight bundle individual and group therapy, and toxicology testing if performed [rowising and/or weight bundle individual and group t
ImportImpor
ImportImpor
Including dispensing and/or administration, subdance use conseling, individual and group therapy, and toxicology testing if performed (provision of the assives by a Medicate-enrolled Opioid Treatment Program)Sa, 122.10Sasta Sasta
administration, substance use consensity, individual and group herapy, and taxicology testing if performed (provision of the services by a Medicare-enrolled Dpiol Treatment Program)SAP2.10Sala Sala Sala Sala Sala Sala Sala Sala
counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-moniled Opioid Treatment Program)\$4,792.10\$334.96\$63.46*\$5,127.06\$5,507.2618DMedicarion assisted treatment, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-moniled Opioid Treatment Program)\$4,792.10\$334.96\$6,4792.10\$5,127.06\$5,5097.26TBDMedicare-moniled opioid Treatment Program)\$1,164.38\$34.96\$16.94\$1,516.28\$1,281.78TBDMedicare-moniled Opioid Treatment Program)\$1,64.38\$34.96\$16.94\$1,516.28\$1,281.78TBDMedicare-moniled Opioid Treatment Program)\$0\$334.96\$0.00\$34.96\$100.46TBDMedicare-moniled Opioid Treatment Program)\$0\$34.96\$0.00\$34.96\$100.46
Image: the tarpy, and toxicology testing if performed (provision of the services by 3 Medicare-enrolled Opioid Treatment, buptenorphine (implant insertion and removal), veekly bundle including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by 3 Medicare-enrolled Opioid Treatment, Program)\$3,192.10\$333.96\$463.46*\$5,127.06\$5,097.26TBDMedication assisted treatment, administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by 3 Medicare-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by 3 Medicare-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltresone; weekly bundle including dispensing and/or administration, substance use consensing, individual and group therapy, and toxicology testing if performed (provision of the services by 3 Medicare-enrolled Opioid Treatment Program)\$1,00.46\$334.96\$0.00\$334.96\$1.00.46
performed (provision of the services by A Medicare-enrolled Opioid Treatment, and removal); weekly bundle including dispensing and/or administration, substance use consening, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment, naltrexone, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment, naltrexone, used bundle nucluding dispensing and/or administration, substance use\$1,164.38\$334.96\$463.46*\$5,127.06\$\$5,087.26TBDMedication assisted treatment, naltrexone, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$\$1,281.78TBDMedication assisted treatment, naltrexone, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$0\$334.96\$0.00\$334.96\$1.00.46TBDMedication assisted treatment, newly bundle not including the drag including substance use\$0\$334.96\$0.00\$334.96\$1.00.46
Image: services by a Medicator-exerolled Opioid Treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapay, and toxicology testing if performed (provision of the services by a Medicate-enrolled Opioid Treatment Program)\$3,1,26.38\$334.96\$463.46*\$5,127.06\$5,127.06\$5,097.26TBDMedication assisted treatment, indefinition, substance use counseling, individual and group therapay, and toxicology testing if performed (provision of the services by a Medicate-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, is ervices by a Medicate-enrolled opioid Treatment Program)\$1,264.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, weekly bundle including the drug individual and group therapay and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$334.96\$0.00\$334.96\$1.04.64
Image: consider treatment ProgramImage: constraint treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opicial Treatment Program)S11.64.38S134.96S13.4.96S1.6.94S1.5.97.26S1.27.06SS.5.097.26TBDMedication assisted treatment, null reatment Program)S1.164.38S1.46.38S1.4.96S1.6.94S1.5.94S1.5.94S1.5.94S1.516.28S1.28.78TBDMedication assisted treatment, nultreatment program)S1.164.38S1.4.96S1.6.94S1.5.94S1.5.94S1.516.28SS1.281.78TBDMedication assisted treatment, nultreatment program)S1.6.94S1.6.94S1.5.94S1.516.28SS1.281.78TBDMedication assisted treatment, nultreatment program)S1.64.38S1.96S1.96S1.94S1.516.28SS1.281.78TBDMedication assisted treatment, nultreatment programS1.64.38S1.96S1.94S1.94S1.96S1.94S1.96S1.94TBDMedication assisted treatment, nultreatment programS1.96S1.96S1.96S1.96S1.96S1.96S1.96TBDMedication assisted treatment, weekly bundle on tinculuing the drug including additione assisted treatment, weekly bundle on tinculuing the drug including additione assisted treatment, weekly bundle on tinculuing the drug including additione assisted treatment, weekly bundle on tinculuing the drug including additione assisted treatment, weekl
TBDMedication assisted treatment, buprenophine (mplant insertion and removal); weekly bundle including dispensing and/or administration, subtance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, subtance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, subtance use counseling, individual and group\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, reatment program)\$1,164.38\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, veekly bundle including dispensing and/or administration, subtance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medication assisted treatment, weekly bundle including dispensing and/or administration, subtance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medication assisted treatment, weekly bundle including substance use\$00\$334.96\$0.00\$334.96\$100.46
bupernorphine (mplant insertion and removal); weekly bundle including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$00\$334.96\$0.00\$334.96\$100.46
and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$0\$334.96\$10.040\$10.46TBDMedicarion substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$00\$334.96\$0.00\$334.96\$100.46
Including dispensing and/or administration, substance use conseling, individual and group therapy, and toxicology testing ifImage: the service of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if\$1,064.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, weekly bundle including tipersonal\$1,064.38\$334.96\$10.46\$100.46TBDMedication assisted treatment, weekly bundle including the enroled\$00\$334.96\$0.00\$334.96\$100.46
administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,164.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltrexone, weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltrexone, weekly bundle including dispensing and/or administration, substance use ervices by a Medicare-enrolled Opioid Treatment Program)\$1,064.38\$334.96\$16.94\$1,281.78TBDMedication assisted treatment, envices by a Medicare-enrolled Opioid Treatment Program)\$0\$334.96\$0.00\$334.96\$100.46weekly bundle not including th drug, including substance use\$0\$334.96\$0.00\$334.96\$100.46
conseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, subtance use courseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$0\$334.96\$0.00\$334.96\$100.46TBDMedication assisted treatment, envices by a Medicare-enrolled Opioid Treatment Program)\$0\$34.96\$0.00\$334.96\$100.46
Image: herapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)S1.64.38S334.96S16.94S1.516.28S1,281.78TBDMedicarion assisted treatment, naltrexone, weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)S0S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00S334.96S0.00<
performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, subtance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$00\$334.96\$0.00\$334.96\$100.46TBDMedication assisted treatment, drug, including substance use drug, including substance use\$00\$334.96\$0.00\$334.96\$100.46
services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if\$0\$334.96\$0.00\$334.96\$100.46TBDMedication assisted treatment, or used using the services by a Medication substance use opioid Treatment Program)\$00\$334.96\$0.00\$334.96\$100.46
Opioid Treatment Program)Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)\$1,64.38\$334.96\$16.94\$1,516.28\$1,281.78TBDMedication assisted treatment, environment of the usekly bundle not including the drug, including substance use\$0\$334.96\$0.00\$334.96\$100.46
Image: constraint of the services by a Medication assisted treatment, including the services by a Medication assisted treatment, additionable to the services by a Medication assisted treatment, the services by a Medic
Image: Constraint of the services by a Medication assisted treatment, natives, weekly bundle including the services by a Medication assisted treatment, additionable to the services by a Medication assisted treatment, weekly bundle of the services by a Medication assisted treatment, the services by a Medication assisted treatment, the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services by a Medication assisted treatment, weekly bundle not including the services assisted treatment to the services astreatment to the services assisted treatment to the services assis
Implementation Imple
Implementation Imple
Including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) Solution
administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) services by a Medicare-enrolled opioid Treatment Program) services by a Medicare-enrolled opioid Treatment Program) so services by a Medicare-enrolled opioid Treatment Program) so so<
courseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) services by a Medicare-enrolled Opioid Treatment Program services by a Medicare-enrolled Streatment Program
therapy, and toxicology testing if performed (provision of the services by a Medicare-norled Dipiold Treatment Program) herapy, and toxicology testing if performed (provision of the services by a Medicare-norled Dipiold Treatment Program) herapy, and toxicology testing if performed (provision of the services by a Medicare-norled Dipiold Treatment Program) herapy, and toxicology testing if performed (provision of the services by a Medicare-norled Dipiold Treatment, Some services by a Medicare service by a Medi
performed (provision of the services by a Medicare-enrolled Opioid Treatment Program) So Sala.96 So Sala.96 So So So TBD Medication assisted treatment, weekly bundle not including the drug, including substance use So Sala.96 So S
services by a Medicare-enrolled Opioid Treatment Program) services by a Medicare-enrolled services by a Medicare-enrolled services by a Medicare-enrolled TBD Medication assisted treatment, weekly bundle not including the drug, including substance use so
Opioid Treatment Program) Opioid Treatment, S Source Source <th< td=""></th<>
TBD Medication assisted treatment, 50 \$334.96 \$334.96 \$0.00 \$334.96 \$100.46 weekly bundle not including the drug, including substance use
weekly bundle not including the drug, including substance use
drug, including substance use
counseling, individual and group
therapy, and toxicology testing if
performed (provision of the
services by a Medicare-enrolled
Opioid Treatment Program)
TBD Medication assisted treatment, - \$0.00 \$ -
medication not otherwise
specified; weekly bundle
including dispensing and/or
administration, substance use
counseling, individual and group
therapy, and toxicology testing, if
performed (provision of the
services by a Medicare-enrolled
Opioid Treatment Program)
Partial Episodes
TBD Medication assisted treatment, \$11.10 \$167.48 \$0.00 \$178.58 \$ 66.58
methadone; weekly bundle
methadone; weekly bundle including dispensing and/or
methadone; weekh bundle including dispensing and/or administration, substance use
methadone; weekly bundle including dispensing and/or administration, substance use courseling, individual and group
methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if
methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the
methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled
methadone; weekhy bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program);
methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled

TBD	Medication assisted treatment,	\$48.51	\$167.48	\$0.00	\$215.99	\$ 103.99	
	buprenorphine (oral); weekly						
	bundle including dispensing						
	and/or administration, substance						
	use counseling, individual and						
	group therapy, and toxicology						
	testing if performed (provision of						
	the services by a Medicare-						
	enrolled Opioid Treatment						
	Program); partial episode. Do not						
	report with GXXX2.						
							108%
TBD		\$1,580.00	\$167.48	\$16.94	\$1,764.42	\$ 1,647.17	
	buprenorphine (injectable);						
	weekly bundle including						
	dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX3.						7%
TBD		\$4,792.10	\$167.48	245.79*	\$4,959.58	\$4,953.33*	
	buprenorphine (implant						
	insertion); weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode (only to be billed						
	once every 6 months). Do not						
	report with GXXX4.						#VALUE!
TBD	report with GXXX4. Medication assisted treatment,	\$0	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant	\$0	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle	\$0 	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or	\$0	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use	50	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
	report with GXXX4. Medication assisted treatment, bupenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group	\$0	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if	50	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the	50	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled	\$0 	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program);	50	\$167.48	265.25*	\$167.48	\$177.09*	#VALUE!
	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report	50	\$167.48	265.25*	\$167.48	\$177.09*	
	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5.						#VALUE! #VALUE!
ТВD	report with GXXX4. Medication assisted treatment, buprenorphice (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment,	\$0 \$4,792.10	\$167.48 \$167.48	265.25* 463.46*	\$167.48 \$4,959.58	\$177.09* \$5,047.03*	
ТВD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion						
ТВD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opiold Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle						
ТВD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or						
ТВD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Don teport with GXXS. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use						
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group herapay, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration, substance use counseling, individual and group						
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if						
TBD	report with GXXX4. Medication assisted treatment, buprenorphice (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration; substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the						
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insection and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled						
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXS. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program);						
TBD	report with GXXX4. Medication assisted treatment, buprenorphice (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report						
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXS. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program);						#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5.	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXS. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXS6.						#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXS. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXK6.	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration; substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXX5. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXX6. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if herdication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy. and toxicology testing if	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Don te report with GXXS2. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX6. Medication assisted treatment, nattrexone; weekly bundle including dispensing and/or administration; substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXX5. Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXX6. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); performed (provision of the services by a Medicare-enrolled Opioid Treatment Program);	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!
TBD TBD	report with GXXX4. Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, buprenorphine (implant insertion administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program); partial episode. Do not report with GXXX5. Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled	\$4,792.10	\$167.48	463.46*	\$4,959.58	\$5,047.03*	#VALUE!

700	Medication assisted treatment,	ée.	\$167.48	ćo. oo	44.67.40	ć 50.00	
		ŞU	\$167.48	\$0.00	\$167.48	\$ 50.23	
	weekly bundle not including the						
	drug, including substance use						
	counseling, individual and group						
	therapy, and toxicology testing if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX8.						233%
	Medication assisted treatment,	•	-	-			
	medication not otherwise						
	specified; weekly bundle						
	including dispensing and/or						
	administration, substance use						
	counseling, individual and group						
	therapy, and toxicology testing, if						
	performed (provision of the						
	services by a Medicare-enrolled						
	Opioid Treatment Program);						
	partial episode. Do not report						
	with GXXX9.						#DIV/0!
Intensity Add-on code			Medication assisted treatment, bupr	\$0.00			#DIV/0!
		\$0	-	-		\$ 26.60	
	counseling or therapy in a week						
	of medication assisted treatment,						
	(provision of the services by a						
	Medicare-enrolled Opioid						
	Treatment Program); List						
	separately in addition to code for						
	primary procedure.						-100%
*Administration of the buprenorphine	implant procedure is crosswalked	to the existing HCPCS codes (G0516, G0517, and G0518) using non-faci	ity values.				#DIV/0!

	C	ommunit	-	or Health Fee Schec 2019	lule
Description of Service	Procedure Code	Modifier 1	Modifier 2	Maximum Fee	Reimbursement and Service Limitations
Assessment Services					
Psychiatric evaluation by physician	H2000	HP		\$210.00 per evaluation	
Psychiatric evaluation by physician - telemedicine	H2000	HP	GT	\$210.00 per evaluation	Medicaid reimburses a maximum of two psychiatric evaluations per recipient, per state fiscal year.*
Psychiatric evaluation by non- physician	H2000	НО		\$150.00 per evaluation	
Brief behavioral health status exam Brief behavioral health status exam - telemedicine	H2010 H2010	но	GT	\$14.66 per quarter hour \$14.66 per quarter hour	There is a maximum daily limit of two quarter-hour units. Medicaid reimburses for brief behavioral health status examinations a maximum of 10 quarter-hour units annually (2.5 hours), per recipient, per state fiscal year.* A brief behavioral assessment is not reimbursable on the same day that a psychiatric evaluation, bio- psychosocial assessment, or in-depth assessment has been completed by a qualified treating practitioner.
Psychiatric review of records	H2000			\$26.00 per review	Medicaid reimburses a maximum of two psychiatric reviews of records, per recipient, per state fiscal year.* This service may not be billed for review of lab work (see medication management).
In-depth assessment, new patient, mental health	H0031	НО		\$125.00 per assessment	
In-depth assessment, new patient, mental health—telemedicine	H0031	НО	GT	\$125.00 per assessment]
In-depth assesment, established patient, mental health	H0031	TS		\$100.00 per assessment	Medicaid reimburses one in-depth assessment, per recipient, per state fiscal year.*
In-depth assessment, established patient, mental health - telemedicine	H0031	TS	GT	\$100.00 per assessment	An in-depth assessment is not reimbursable on the same day for the same recipient as a biopsychosocial evaluation.

					A bio-psychosocial evaluation is not reimbursable for
In-depth assessment, new patient, substance abuse	H0001	НО		\$125.00 per assessment	the same recipient after an in-depth assessment has been completed, unless there is a documented change in the recipient's status and additional
In-depth assessment, new patient, substance abuse—telemedicine	H0001	НО	GT	\$125.00 per assessment	in the recipient's status and additional information must be gathered to modify the recipient's treatment plan.
In-depth assessment, established patient, substance abuse	H0001	TS		\$100.00 per assessment	
In-depth assessment, established patient, substance abuse— telemedicine	H0001	TS	GT	\$100.00 per assessment	
Bio-psychosocial Evaluation, mental health	H0031	HN		\$48.00 per assessment	Medicaid reimburses one biopsychosocial evaluation, per recipient, per state fiscal year.*
Bio-psychosocial Evaluation, mental health - telemedicine	H0031	HN	GT	\$48.00 per assessment	A bio-psychosocial evaluation is not reimbursable on
Bio-psychosocial evaluation, substance abuse	H0001	HN		\$48.00 per assessment	the same - day for the same recipient as an in-depth assessment.
Bio-psychosocial evaluation, substance abuse - telemedicine	H0001	HN	GT	\$48.00 per assessment	
Psychological testing	H2019			\$15.00 per quarter hour	Medicaid reimburses a maximum of 40 quarter-hour units (10 hours) of psychological testing per state fiscal year.*
Limited functional assessment, mental health	H0031			\$15.00 per assessment	Medicaid reimburses a maximum of three limited functional
Limited functional assessment, mental health - telemedicine	H0031	GT		\$15.00 per assessment	assessments, per recipient, per state fiscal year.*
Limited functional assessment, substance abuse	H0001			\$15.00 per assessment	
Limited functional assessment, substance abuse - telemedicine	H0001	GT		\$15.00 per assessment	
Treatment Plan Development and M	odification	T	ī	•	
Treatment plan development, new and established patient, mental health	H0032			\$97.00 per event	Medicaid reimburses for the development of one treatment plan per provider, per state fiscal year.*
Treatment plan development, new and established patient, substance abuse	T1007			\$97.00 per event	Medicaid reimburses for a maximum total of two treatment plans per recipient per state fiscal year.* The reimbursement date for treatment plan development is the day it is authorized by the treating practitioner.

Treatment plan review, mental health Treatment plan review, substance	H0032 T1007	TS TS		\$48.50 per event \$48.50 per event	Medicaid reimburses a maximum of four treatment plan reviews, per recipient, per state fiscal year.* The reimbursement date for a treatment plan review is the day it is authorized by the treating practitioner.	
abuse Medical and Psychiatric Services				· · ·		
Medication management	T1015			\$60.00 per event	Medicaid reimburses medication management as medically necessary.	
Medication management - telemedicine	T1015	GT		\$60.00 per event	Medication management is not reimbursable on the same day, for the same recipient, as brief group medical therapy or brief individual medical psychotherapy.	
Brief individual medical psychotherapy, mental health	H2010	HE		\$15.00 per quarter hour	There is a maximum daily limit of two quarter-hour units.	
Brief individual medical psychotherapy, mental health - telemedicine	H2010	HE	GT	\$15.00 per quarter hour	Medicaid reimburses a maximum of 16 quarter-hour units (4 hours) of brief individual medical	
Brief individual medical psychotherapy, substance abuse	H2010	HF		\$15.00 per quarter hour	 psychotherapy, per recipient, per state fiscal year.* Brief individual medical psychotherapy is not reimbursable on the same day, for the same recipient, as brief group medical therapy or medication management. 	
Brief individual medical psychotherapy, substance abuse - telemedicine	H2010	HF	GT	\$15.00 per quarter hour		
Brief group medical therapy	H2010	HQ		\$8.65 per quarter hour	There is a maximum daily limit of two quarter-hour units. Medicaid reimburses a maximum of 18 quarter-hour units (4.5 hours) of group medical therapy, per recipient, per state fiscal year.* Brief group medical therapy is not reimbursable on the same day, for the same recipient as brief individual medical psychotherapy or behavioral health-related medical services: verbal interactions, medication management.	

Behavioral health medical screening, mental health	T1023	HE	\$43.62 per event	Medicaid reimburses two behavioral health medical screening services, per recipient, per state fiscal year.*	
Behavioral health medical screening, substance abuse	T1023	HF	\$43.62 per event	Behavioral health-related medical screening services are not reimbursable on the same day, for the same recipient, as behavioral health-related medical services: verbal interactions, medication management.	
Behavioral health-related medical services: verbal interaction, mental health	H0046		\$15.00 per event		
Behavioral health-related medical services: verbal interaction, mental health - telemedicine	H0046	GT	\$15.00 per event	Medicaid reimburses 52 behavioral health-related medical services: medical procedures, per recipient, per state fiscal year.* Behavioral health-related medical services: verbal interactions are not reimbursable on the same day as behavioral health screening services.	
Behavioral health-related medical services: verbal interaction, substance abuse	H0047		\$15.00 per event		
Behavioral health-related medical services: verbal interaction, substance abuse - telemedicine	H0047	GT	\$15.00 per event		
Behavioral health-related medical services: medical procedures, mental health	T1015	HE	\$10.00 per event	Medicaid reimburses 52 behavioral health-related	
Behavioral health-related medical services: medical procedures, substance abuse	T1015	HF	\$10.00 per event	medical services: medical procedures, per recipient, per state fiscal year.*	
Behavioral health-related medical services: alcohol and other drug screening specimen	H0048		\$10.00 per event	Medicaid reimburses 52 behavioral health – related medical services: alcohol and other drug screening specimen collections, per recipient, per state fiscal year.*	
Medication-assisted treatment services	H0020		\$67.48 weekley rate	Medicaid reimburses medication assisted treatment services 52 times, per recipient, per state fiscal year.* The service is billed one time per seven days. This service is not reimbursable using any other procedure code.	

Behavioral Health Therapy Services						
Individual and family therapy	H2019	HR		\$18.33 per quarter	Medicaid reimburses a maximum of 104 quarter-hour units (26 hours) of individual and family therapy	
Individual and family therapy- telemedicine	H2019	HR	GT	\$18.33 per quarter	services, per recipient, per state fiscal year.* There is a maximum daily limit of four quarter-hour units (1 hour).	
Group therapy	H2019	HQ		\$6.67 per quarter hour	Medicaid reimburses a maximum of 156 quarter-hour units (39 hours) of group therapy services, per recipient, per state fiscal year.*	
Behavioral health day services, mental health	H2012			\$12.50 per hour	Medicaid reimburses a maximum of 190-hour units (47.5 hours; 11.9 half-days) per recipient, per state fiscal year.* Medicaid will not reimburse for behavioral health day services the same day as psychosocial rehabilitation services.	
Behavioral health day services, substance abuse	H2012	HF		\$12.50 per hour		
Community Support and Rehabilitat	ive Services	1		1		
Psychosocial rehabilitation services	H2017			\$9.00 per quarter hour	Medicaid reimburses a maximum of 1,920 units (480 hours; 20 days) of psychosocial rehabilitation services, per recipient, per state fiscal year.* These units count against clubhouse service units.	
Clubhouse services	H2030			\$5.00 per quarter hour	Medicaid reimburses clubhouse services for a maximum of 1920 quarter-hour units (480 hours; 20 days) annually, per recipient, per state fiscal year.* These units count against psychosocial rehabilitation units of service.	
Therapeutic Behavioral On-Site Services for Recipient Under Age of 21 Years						
Therapeutic behavioral on-site services, therapy	H2019	НО		\$16.00 per quarter hour	Medicaid reimburses therapeutic behavioral on-site therapy services a maximum combined limit of a total of 36, 15-minute units per month (9 hours) by a master's level or certified behavioral analyst.	

Therapeutic behavioral on-site services, behavior management		HN	\$10.00 per quarter hour	Medicaid reimburses therapeutic behavioral on-site behavior management and therapeutic behavioral on- site therapy services for a maximum combined total of 36, 15-minute units per month by a master's level practitioner, certified behavioral analyst, or certified associate behavioral analyst.
Therapeutic behavioral on-site services, therapeutic support			\$4.00 per quarter hour	Medicaid reimburses therapeutic behavioral on-site therapeutic support services for a maximum of 128 quarter-hour units per month (32 hours), per recipient.

Opioid Treatment Program Reimbursement Re-bundling Proposal

Maryland Department of Health and Mental Hygiene | April 22, 2016

The Department reviewed close to 50 letters and emails submitted by stakeholders providing comments and suggestions regarding the December 14th re-bundling proposal. After carefully reviewing all stakeholder input the Department is presenting the revised proposal for a second review, including an additional stakeholder comment period. This document presents changes proposed by the Department and integrates them with the original proposal.

Executive Summary

Maryland Medicaid proposes re-bundling the methadone reimbursement rates to include a \$ 56.00 per week per patient bundle for methadone maintenance, and adds the ability for Opioid Treatment Programs (OTP) to bill for outpatient counseling (H0004 and H0005) separately, as clinically necessary.

In response to stakeholder comments on the December 14, 2015 proposal, the Department proposes the following changes (described in more detail throughout this proposal):

- 1. Increase the proposed bundled rate for methadone maintenance (H0020) from \$ 42.00 per week to \$ 56.00 per week
- 2. Increase the proposed guest dosing rate for the guest OTP from \$ 3.00 per day to \$ 8.00 per day (the daily equivalent of the weekly rate)
- 3. Increase the proposed bundled rate for buprenorphine maintenance (H0047) from \$ 35.00 per week to \$ 49.00 per week (same weekly rate as methadone less the cost of the medication which is reimbursed separately)
- 4. Add the ability for OTPs to bill for H0016 Medication Assisted Treatment Induction for methadone treatment (\$ 200.00 for the initial induction)
- 5. Add the ability for OTP Physicians and Nurse Practitioners to bill for periodic medication management visits

The goal of this program is to address the practical needs of providers and participants and create flexibility in the administration of Medication Assisted Treatment in order to better integrate the provision of counseling and medical services. This proposal aims to strengthen continuity of care across the substance use disorder service spectrum. The re-bundled weekly rate will allow providers to bill for the outpatient counseling services provided by an OTP but also allow participants to continue receiving their methadone when they need to attend more intensive levels of treatment, such as treatment in an intensive outpatient program. This change will also enable the Department to address the needs of participants requiring temporary dosing at their non-home OTP site (guest dosing) and creates a mechanism of payment for providers whose participants are clinically appropriate to receive take home medication.

Current Methadone Reimbursement Structure

In accordance with federal and state regulation, OTPs are required to provide counseling as clinically indicated to their patients¹. Currently Maryland Medicaid reimburses OTPs for methadone maintenance through a bundled rate of \$80.00 per week per patient (H0020). According to COMAR 10.09.80.05.E, this bundle includes a comprehensive substance use disorder assessment; an individualized treatment plan; methadone dosing; substance use disorder and related counseling; medical services; ordering and administering drugs; and discharge planning. Clinically appropriate counseling is currently an expected part of the bundle for methadone maintenance. Additionally, this weekly bundled rate can only be billed by OTPs when a patient is seen in the clinic at least once that week.

Proposed OTP Methadone Maintenance Reimbursement Structure

OTP providers will continue to bill the current reimbursement code for methadone maintenance (H0020). This code will be adjusted to be a weekly bundled rate of \$ 56.00 per week per participant, which includes the following services:

- Managing medical plan of care
- A minimum of one face to face meeting in a month
- Methadone dosing
- Nursing services related to dispensing methadone
- Ordering and administering drugs
- Point of care toxicology testing (G0477)
- Coordination with other clinically indicated services

Updates to the proposal post review of stakeholder comments include the following:

- 1. The Department reconsidered the original proposed rate of \$ 42.00 per week and has adjusted by more than 30%. The new proposed rate for the bundled service (which now excludes initial medical services which will be separately reimbursed) is \$ 56.00 per week.
- 2. The Department proposes to add the ability for OTPs to bill for medication assisted treatment induction using the H0016 code that is currently used for buprenorphine induction (\$ 200.00 per induction), in recognition of the time intensity involved with the induction process.
- 3. Additionally, the Department proposes allowing OTP Physicians and Nurse Practitioners to bill for up to five visits for medication management annually (E&M codes).

Summary of changes: In the first week an OTP provider will be able to bill for H0020 Methadone Maintenance (\$ 56.00 per week), H0001 Alcohol and/ drug assessment (\$ 142.00 per assessment), and H0016 Medication Assisted Treatment Induction (\$ 200.00). E&M codes will not be reimbursed in the first week of treatment, concurrently with H0016 Induction.

¹ CFR 42 §8.12; COMAR 10.09.80.05

Counseling:

Under this proposal, counseling services may be billed by OTPs in addition to the bundled rate. However, in the first week OTPs may not bill for counseling codes as counseling is included in the MAT Induction code (H0016 \$ 200.00). After the induction week, OTPs may choose to bill H0004 and H0005 procedure codes for individual and group counseling respectively, as clinically indicated. OTPs are responsible for Level 1 outpatient counseling to their enrolled patients. No other provider can be reimbursed for Level 1 outpatient counseling while the participant is receiving Medication Assisted Treatment from an OTP.

If there is clinical necessity for a more intensive level of treatment, OTPs would refer their patient to a Certified Addictions Program (PT 50). OTP providers that are certified to deliver IOP level of care would then need to be enrolled with Medicaid as a Provider Type 50 in order to obtain authorization and claims payment for IOP services.

Labs:

In this proposal, there are no changes to billing of lab codes from the current methadone maintenance bundle. Urinalysis (random drug testing) is included in the proposed bundled rate for methadone maintenance. The proposed rate includes G0477 (previously G0434) drug tests which may be billed by appropriately licensed providers. All other lab testing must be sent to labs.

Guest Dosing for Methadone

When a patient needs to receive methadone treatment at an OTP other than the one they regularly attend, they may need a guest dose from another OTP. Currently, there is no mechanism for Maryland Medicaid to reimburse the guest OTP treatment site. Under this proposal the Department would authorize payment of \$ 8.00 per day to the provider delivering the guest dosing. The guest dosing provider would need to coordinate with the "home" provider to ensure correct dosage and avoid duplicative dosing.

The Department recognizes that guest dosing requires a significant amount of time and effort that is equivalent to a normal week. Therefore the Department is proposing that the home OTP will receive the bundled weekly rate (\$ 56.00 per week) and the guest dosing OTP will receive a daily equivalent of the weekly bundled rate (\$ 8.00 per day or \$56.00 per week) only for days medication is managed by the guest dosing provider.

Participants will be allowed up to 30 days of guest dosing per year, with the ability for their home provider to request additional units for special circumstances through clinical review. It will be the responsibility of the guest provider to be in touch with the home provider in order to receive information about dosing and ensure that the home provider is not dosing while the participant is receiving their doses from the guest OTP.

Proposed OTP Buprenorphine Reimbursement Structure

Similar to the proposed methadone reimbursement plan, OTP providers will continue to bill the current reimbursement code for buprenorphine maintenance (H0047). However, this code will be reduced to be a bundled rate of \$ 49.00 per week per patient, to cover the following:

- Medical plan of care
- Once a month face to face meeting
- Buprenorphine dosing
- Nursing services related to dispensing
- Ordering and administering drugs
- Point of care toxicology testing (G0477)
- Coordination with clinically indicated services

Updates to the proposal post review of stakeholder comments include the following:

- 1. The Department reconsidered the original proposed rate of \$ 35.00 per week and has adjusted by more than 30%. The new proposed rate for the bundled service (which now excludes initial medical services which will be separately reimbursed) is \$ 49.00 per week.
- 2. Additionally, the Department proposes allowing OTP Physicians and Nurse Practitioners to bill for up to five visits for medication management annually (E&M codes).

The reimbursement rate for buprenorphine inductions will remain the same (H0016 \$200.00); as will the reimbursement rate for buprenorphine itself when purchased and administered by the OTP (J8499).

Face to Face Requirements

According to federal regulations 42 CFR 8.12, the maximum time allowed for take home methadone treatment is for 31 days. This means all patients must be seen at least once a month in person.

OTPs are required to update the individualized treatment plan according to state regulations every 90 days via a face to face evaluation (COMAR 10.47.02.04; 10.47.02.11). However, if a patient at an OTP is receiving take home methadone treatment and has been stable for one year, the treatment plan may be updated every 180 days.

Process

Providers and stakeholders will have 21 days to comment on this revised proposal. All comments should be sent to dhmh.medicaidsud@maryland.gov. The Department will be accepting comments until Monday, May 13, 2016.

At the conclusion of that comment period, the Department will evaluate the next steps, which will include seeking approval from CMS and promulgating regulations.

Overview of Current Medication Assisted Treatment Reimbursement Compared to Proposed Reimbursement						
	Current	Proposed				
Services included in the bundle	 Comprehensive substance use disorder assessment; An individualized treatment plan; Once a week face to face meeting Medication Assisted Treatment dosing; Substance use disorder and related counseling; Medical services; Ordering and administering drugs; Point of care toxicology testing (G0477); and Discharge planning 	 Medical plan of care Once a month face to face meeting Medication Assisted Treatment dosing Nursing services related to dispensing methadone Ordering and administering drugs Point of care toxicology testing (G0477) Coordination with other clinically indicated services 				
Allowed Methadone Reimbursement Codes	 H0020 Methadone Maintenance (\$ 80.00 per week) H0001 Alcohol and/or drug assessment (\$ 142.00 per assessment) 	 H0020 Methadone Maintenance (\$ 56.00 per week) H0001 Alcohol and/or drug assessment (\$ 142.00 per assessment) H0016 Medication Assisted Treatment Induction (\$ 200.00 per induction) H0004 Individual Outpatient Counseling (\$ 20.00 per 15 minutes) H0005 Group Outpatient Counseling (\$ 39.00 per 60-90 minute session) E&M codes for medication management (up to 5 visits per year), not to be billed concurrently with induction (H0016) 				
Allowed Buprenorphine Reimbursement Codes	 H0016 Buprenorphine Induction (\$ 200.00) H0047 Buprenorphine Maintenance (\$ 75.00) H0001 Alcohol and/or drug assessment (\$ 142.00 per assessment) J8499 Buprenorphine (8mg or 2mg) 	 H0016 Medication Assisted Treatment Induction (\$ 200.00 per induction) H0047 Buprenorphine Maintenance (\$ 49.00 per week) H0001 Alcohol and/or drug assessment (\$ 142.00 per assessment) H0004 Individual Outpatient Counseling (\$ 20.00 per 15 minutes) H0005 Group Outpatient Counseling (\$ 39.00 per 60-90 minute session) E&M codes for medication management (up to 5 visits per year), not to be billed concurrently with induction (H0016) J8499 Buprenorphine (8mg or 2mg) 				
IOP Services	When a patient is receiving MAT from an OTP and requires higher intensity services such as IOP from a	When a patient is receiving MAT from an OTP and requires higher intensity services such as IOP from a type 50, both providers can be				

April 22, 2016

	type 50, only one of the providers can be reimbursed.	authorized and receive reimbursement for services.
Guest Dosing for Methadone	Currently there is no formalized way for guest dosing providers to be reimbursed by Medicaid.	<u>Home OTP</u> : Reimbursed \$ 56.00 per week <u>Guest dosing OTP</u> : Reimbursed a daily equivalent of the weekly bundled rate (\$ 8.00 per day or \$56.00 per week) only for days medication is managed by the guest dosing agency
Face to Face Requirement	In order to be reimbursed the weekly bundle, the participant must be seen in person during the week.	For participants receiving take home doses, the OTP may be reimbursed the weekly bundle as long as the participant is seen once during the month.



Table of Contents

Introduction	3
SECTION 1	3
MITS Enrollment: Adding an OTP Provider Specialty	3
National Drug Code (NDC)	3
SECTION 2 – Billing Guidance	5
OhioMHAS Licensed Opioid Treatment Programs (Methadone)	5
SAMHSA Certified Opioid Treatment Programs (Buprenorphine)	8

January 1 – June 30 Billing Manual Updates						
Version	Description of Changes	Last Editor	Release			
			Date			
Version 1.0	Final Version 1.0	State Policy Team	12.16.16			
Version 1.0.a	Added "HG" modifier to J8499 in Table 1-3	State Policy Team	12.23.16			
Version 1.0.b	Updated pricing reference for J2310 – Injectable/Nasal Naloxone Deleted "Preparation for July 1, 2017" section	State Policy Team	6.8.17			
Version 1.1	Rate updates	State Policy Team	9.16.19			
Version 1.2	Correct hyperlink for S5000 and S5001	State Policy Team	9.25.19			

The rest of this page intentionally left blank

Introduction

The Ohio Departments of Medicaid (ODM) and Mental Health and Addiction Services (OhioMHAS) has created this Opioid Treatment Program (OTP) Medicaid manual to document changes that are being made for OTP services provided on and after January 1, 2017. All other changes associated with the behavioral health redesign will be implemented July 1, 2017 at which time this manual will be incorporated into the broader Ohio Medicaid behavioral health provider manual.

SECTION 1

MITS Enrollment: Adding an OTP Provider Specialty

Providers already enrolled as a provider type 95 (community substance use disorder program) with provider specialty 950 AND either licensed by OhioMHAS as a methadone administration program (provider specialty 951) AND/OR certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) as an OTP (provider specialty 953) may request the addition of a provider specialty for methadone administration and/or buprenorphine based medication administration. OTPs must contact OhioMHAS via e-mail at <u>MHAS-BHSupport@mha.ohio.gov</u>. Please indicate in the subject line "Request to add OTP specialty" and include in the e-mail the following:

 Request to add provider specialty for methadone administration and/or buprenorphine based medication administration.
 NOTE: Existing methadone administration programs that are enrolled in the Ohio

Medicaid program must follow this process to add the buprenorphine based medication administration provider specialty to bill this service coding.

- 2) Attach the appropriate certification: OhioMHAS methadone license and/or SAMHSA OTP certificate.
- 3) Contact name, phone number and agency billing provider id for any follow-up.

National Drug Code (NDC)

With the exception of hospital claims, federal law requires that any code for a drug covered by Medicaid must be submitted with the 11-digit NDC assigned to each drug package. The NDC specifically identifies the manufacturer, product and package size. Each NDC is an 11-digit number, sometimes including dashes in the format 55555-4444-22. When submitting claims to Medicaid, providers should submit each NDC using the 11-digit NDC **without** dashes or spaces. The NDC included on the claim must be the exact NDC that is on the package used by the provider.

Some drug packages include a 10-digit NDC. In this case, the provider should convert the 10 digits to 11 digits when reporting this on the claim. When converting a 10-digit NDC to an 11-digit NDC, a leading zero should be added to only one segment:

- If the first segment contains only four digits, add a leading zero to the segment;
- If the second segment contains only three digits, add a leading zero to the segment;
- If the third segment contains only one digit, add a leading zero to the segment.

All claims reporting NDC information must be submitted either as an Electronic Data Interchange (EDI) transaction or through the MITS Web Portal. The NDC will be required at the detail level when a claim is submitted with a code that represents a drug (e.g., J-codes and Scodes).

The following table contains abbreviations for professional practitioners referenced in this manual:

Pract	itioner Abbreviation Key
MD/DO	Physician
CNS	Clinical nurse specialist
CNP	Certified nurse practitioner
PA	Physician assistant
RN	Registered nurse
LPN	Licensed practical nurse

The rest of this page intentionally left blank

SECTION 2 – Billing Guidance

The following medication code will continue to be available for all substance use disorder (SUD) treatment providers (Medicaid provider type 95 with provider specialty 950). It is listed here as OTPs will have a dual use for it. Under their general SUD program (95/950) it is used for induction/titration in accordance with current Ohio Medicaid policy

Table 1-1 SUD Treatment Programs				
	Provider Ty	pe 95/950		
Service	Medication	Code	Modifier	Rate
Medication	Buprenorphine, oral, 1 mg.	J8499	_	\$0.55
Unit Value	HCPCS designation			

As an OTP (95/951 or 95/953), J8499 will be used for oral naltrexone (see following OTP sections for additional details).

OhioMHAS Licensed Opioid Treatment Programs (Methadone)

The following section applies to services delivered on or after January 1, 2017 by a substance use disorder Medicaid provider type 95 with provider specialty 951:

- 1. Ohio Medicaid recognizes and enrolls OTPs that are licensed by OhioMHAS under Ohio Administrative Code 5122-29-35. These OhioMHAS licensed programs are authorized to administer methadone.
- 2. OTPs must bill for the administration of methadone using H0020 with the HF modifier for a daily administration **or** H0020 with the appropriate modifier for take home doses administered.
 - a. If patient is seen every day in order to receive methadone, modifier HF must be used with H0020.
 - b. OTPs will bill H0020 with a modifier representing 1, 2, 3 or 4 weeks of take home medication for patients who have met the requirements of 42 CFR § 8.12(h)(4)(i). The OTP must maintain documentation in the patient record that supports the amount of take home doses administered.
 - c. If any weekly administration modifier has been billed, the OTP cannot bill for any other face-to-face visits of H0020 during that time period.
 - d. Date of service on the claim for H0020 must be the date the patient was seen in the office by the OTP in order to receive their medication.
- 3. OTPs may bill 99211 for the nasal administration of naloxone (J2310). This coding combination is only used when the naloxone is administered nasally on site.
- 4. OTPs may bill 96372 for the injectable administration of naloxone (J2310). This coding combination is only used when the naloxone is administered by injection on site.

- 5. OTPs may bill for the cost of injectable/nasal naloxone (J2310) under their Ohio Board of Pharmacy license and in conformance with the Ohio Board of Pharmacy requirements.
- 6. OTPs may bill for the cost of injectable/nasal naloxone (J2310) when provided in accordance with Ohio Revised Code 4731.941.
- 7. OTPs may bill for the cost of oral naltrexone (J8499) under their Ohio Board of Pharmacy license.
- 8. OTPs may bill for the collection of blood using venipuncture (36415), per draw when the sample is sent to an outside laboratory for testing.
- 9. All of the OTP services must be performed by one of the following medical professionals within their scope of practice: physician, physician assistant, clinical nurse specialist, certified nurse practitioner, licensed practical nurse, or a registered nurse.

Please reference Table 1-2 on the following page for additional information on service coding, rates and modifiers.

The rest of this page intentionally left blank

	Table 1-2 Opio	<mark>id Treatment</mark>	Program	S	
Prov	vider Type 95/951 – St		Methador	e Program	
Service	Description	Provider Type	Code	Modifier	Rate
	Daily			HF	\$16.38
	Weekly (2 – 7 days)	MD/DO,		TV	\$114.66
Methadone Administration	Two Weeks (8 – 14 days)	CNS, NP, PA,	H0020	UB	\$229.32
7 Minimistration	Three Weeks (15 – 21 days)	RN, LPN		TS	\$343.98
	Four Weeks (22 – 28 days)			HG	\$458.64
Other Medication	E&M Established Patient (for OTP use with Nasal Narcan Administration)	MD/DO, CNS, CNP, PA, RN, LPN	99211	-	\$22.31
Administration	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	MD/DO, CNS, CNP, PA, RN, LPN	96372	-	\$21.39
	Oral Naltrexone, per 50 mg tablet	-	J8499	HG	\$1.20
Medications	Injection/Nasal, naloxone (Narcan), 1mg	_	J2310	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
Laboratory Services	Collection of venous blood by venipuncture	Per CPT guidelines ¹	36415	-	\$ See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service.
Unit Value	CPT or HCPCS designa	tion			

¹ Medicaid will not reimburse for the collection of venous blood when providers performs testing in their facilities. Nor will Medicaid pay when it is part of an E&M visit. Medicaid will only reimburse separately for the collection of venous blood when a provider draws the blood and sends it to a non-related outside facility without performing any testing.

SAMHSA Certified Opioid Treatment Programs (Buprenorphine)

The following section applies to services delivered on or after January 1, 2017 by a substance use disorder Medicaid provider type 95 with provider specialty 953:

- Ohio Medicaid recognizes and enrolls OTPs that are certified the by the Substance Abuse and Mental Health Services Administration (SAMHSA) under 42 CFR §8.11(21 U.S.C. 823(g)(1)). These SAMHSA certified programs are authorized to provide medication assisted treatment by administering buprenorphine based medications.
- 2. OTPs must bill for the administration of buprenorphine based medications using T1502 with the HF modifier for a daily administration **or** T1502 with the appropriate modifier for take home doses.
 - a. If patient is seen every day in order to receive a buprenorphine based medication, modifier HF must be used with T1502.
 - b. OTP will bill T1502 with a modifier to represent 1, 2, 3 or 4 weeks of take home medication. The OTP must maintain documentation in the patient record that supports the amount of take home doses administered.
 - c. If any weekly administration modifier has been billed, the OTP cannot bill for any other face-to-face visits of T1502 during that time period.
 - d. Date of service on the claim for T1502 must be the date the patient was seen in the office by the OTP in order to receive their medication.
- 3. OTPs must bill the appropriate J code (see chart below) for the buprenorphine based medication that was administered. OTPs may bill for take home doses using S5000 or S5001.
- 4. OTPs may bill 99211 for the nasal administration of naloxone (J2310). This coding combination is only used when the naloxone is administered nasally on site.
- 5. OTPs may bill 96372 for the injectable administration of naloxone (J2310). This coding combination is only used when the naloxone is administered by injection on site.
- 6. OTPs may bill for the cost of injectable/nasal naloxone (J2310) under their Ohio Board of Pharmacy license and in conformance with the Ohio Board of Pharmacy requirements.
- 7. OTPs may bill for the cost of injectable/nasal naloxone (J2310) when provided in accordance with Ohio Revised Code 4731.941.
- 8. OTPs may bill for the cost of oral naltrexone (J8499) under their Ohio Board of Pharmacy license.
- 9. OTPs may bill for the collection of blood using venipuncture (36415), per draw when the sample is sent to an outside laboratory for testing.
- 10. All of the OTP services must be performed by one of the following medical professionals within their scope of practice: physician, physician assistant, clinical nurse specialist, certified nurse practitioner, licensed practical nurse, or a registered nurse.

	Table 1-3 Opi	oid Treatme	nt Progra	ams	
Prov	ider Type 95/953 – SAMH	SA Certified	Opioid	Treatment I	Program
Service	Description	Provider Type	Code	Modifier	Rate
	Daily			HF	\$16.38
	Weekly (2 – 7 days)	MD/DO, CNS,		TV	\$114.66
Buprenorphine/ Naloxone	Two Weeks (8 – 14 days)	CNP, PA,	T1502	UB	\$229.32
Administration	Three Weeks (15 – 21 days)	RN, LPN		TS	\$343.98
	Four Weeks (22 – 28 days)			HG	\$458.64
Other	E&M Established Patient (for OTP use with Nasal Narcan Administration)	MD/DO, CNS, CNP, PA, RN, LPN	99211	-	\$22.31
Medication Administration	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	MD/DO, CNS, CNP, PA, RN, LPN	96372	-	\$21.39
	Buprenorphine, oral, 1 mg.	-	J0571	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
	Buprenorphine/naloxone, oral, less than or equal to 3 mg.	-	J0572	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
	Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg.	-	J0573	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg.	-	J0574	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
Medications	Buprenorphine/naloxone, oral, greater than 10 mg.	-	J0575	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
	Buprenorphine/naloxone, generic, per 1mg buprenorphine/0.25mg naloxone ²	-	S5000	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
	Buprenorphine, generic, per 1 mg.		S5000	HD	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
	Buprenorphine/naloxone, brand, per 1mg	-	S5001	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service

	buprenorphine/0.25mg naloxone ²				
	Oral Naltrexone, per 50 mg tablet	-	J8499	HG	\$1.20
	Injection/Nasal, naloxone (Narcan), 1mg	-	J2310	-	See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service
Laboratory Services	Collection of venous blood by venipuncture	Per CPT guidelines ¹	36415	-	\$ See <u>Medicaid fee</u> <u>schedule</u> in effect for date of service.
Unit Value	CPT or HCPCS designation				

¹ Medicaid will not reimburse for the collection of venous blood when providers performs testing in their facilities. Nor will Medicaid pay when it is part of an E&M visit. Medicaid will only reimburse separately for the collection of venous blood when a provider draws the blood and sends it to a non-related outside facility without performing any testing.

² Per FDA regulations, the maximum recommended milligrams of a buprenorphine based medication and individual patient should be taking per day is twenty-four.

Appendix B: Virginia Medicaid Rates MAGELLAN VA MEDICAID/DMAS RATES

EFFECTIVE: <u>7/1/2018</u>

EFFECTIVE: <u>//1/2018</u>							
DESCRIPTION	CPT® CODE	Age or Setting	Modifier	PHYSICIAN	PSYCHOLOGIST	MASTER'S LEVEL	CLINICAL NURSE SPECIALIST
Psychiatric Diagnostic Evaluation - no medical svcs*	90791	IP	w/ or w/o GT	\$104.18	\$93.76	\$70.32	\$70.32
Psychiatric Diagnostic Evaluation - no medical svcs*	90791	OP	w/ or w/o GT	\$110.91	\$99.82	\$74.86	\$74.86
Psychotherapy w/ patient, 30 min*	90832	IP	w/ or w/o GT	\$51.80	\$46.62	\$34.97	\$34.97
Psychotherapy w/ patient, 30 min*	90832	OP	w/ or w/o GT	\$53.85	\$48.47	\$36.35	\$36.35
Psychotherapy w/ patient, 45 min*	90834	IP	w/ or w/o GT	\$69.06	\$62.15	\$46.62	\$46.62
Psychotherapy w/ patient, 45 min*	90834	OP	w/ or w/o GT	\$71.99	\$64.79	\$48.59	\$48.59
Psychotherapy w/ patient, 60 min*	90837	IP	w/ or w/o GT	\$103.89	\$93.50	\$70.13	\$70.13
Psychotherapy w/ patient, 60 min*	90837	OP	w/ or w/o GT	\$107.98	\$97.18	\$72.89	\$72.89
Family/Couples Psychotherapy w/o patient present, 50 min*	90846	IP	w/ or w/o GT	\$83.70	\$75.33	\$56.50	\$56.50
Family/Couples Psychotherapy w/o patient present, 50 min*	90846	OP	w/ or w/o GT	\$86.91	\$78.22	\$58.66	\$58.66
Family/Couples Psychotherapy w/ patient present, 50 min*	90847	IP	w/ or w/o GT	\$87.21	\$78.49	\$58.87	\$58.87
Family/Couples Psychotherapy w/ patient present, 50 min*	90847	OP	w/ or w/o GT	\$90.43	\$81.39	\$61.04	\$61.04
Group Psychotherapy*	90853	IP	w/ or w/o GT	\$20.48	\$18.43	\$13.82	\$13.82
Group Psychotherapy*	90853	OP	w/ or w/o GT	\$20.48 \$21.66	\$19.49	\$13.82 \$14.62	\$14.62
	+90785	IP		\$21.00 \$11.41	\$10.27	\$14.02 \$7.70	\$7.70
Interactive Complexity Add-on				\$11.41 \$12.00	\$10.27 \$10.80		\$8.10
Interactive Complexity Add-on	+90785	OP	w/ or w/o CT	-		\$8.10	
Psychiatric Diagnostic Evaluation - w/ medical svcs*	90792	IP OP	w/ or w/o GT	\$117.35	N/B	N/B	\$79.21
Psychiatric Diagnostic Evaluation - w/ medical svcs*	90792	OP	w/ or w/o GT	\$124.08	N/B	N/B	\$83.75
Psychotherapy w/ patient, 30 min, w/ E&M svc*	+90833	IP	w/ or w/o GT	\$54.14	N/B	N/B	\$36.54
Psychotherapy w/ patient, 30 min, w/ E&M svc*	+90833	OP	w/ or w/o GT	\$56.19	N/B	N/B	\$37.93
Psychotherapy w/ patient, 45 min, w/ E&M svc*	+90836	IP	w/ or w/o GT	\$68.19	N/B	N/B	\$46.03
Psychotherapy w/ patient, 45 min, w/ E&M svc*	+90836	OP	w/ or w/o GT	\$70.82	N/B	N/B	\$47.80
Psychotherapy w/ patient, 60 min, w/ E&M svc*	+90838	IP	w/ or w/o GT	\$90.13	N/B	N/B	\$60.84
Psychotherapy w/ patient, 60 min, w/ E&M svc*	+90838	OP	w/ or w/o GT	\$93.65	N/B	N/B	\$63.21
Electroconvulsive Therapy (E.C.T.)	90870	IP		\$91.60	N/B	N/B	N/B
Electroconvulsive Therapy (E.C.T.)	90870	OP		\$145.15	N/B	N/B	N/B
Office Outpatient Visit, New patient, minor*	99201	<21/IP	w/ or w/o GT	\$20.72	N/B	N/B	\$13.99
Office Outpatient Visit, New patient, minor*	99201	<21/OP	w/ or w/o GT	\$34.35	N/B	N/B	\$23.19
Office Outpatient Visit, New patient, minor*	99201	>20/IP	w/ or w/o GT	\$18.17	N/B	N/B	\$12.26
Office Outpatient Visit, New patient, minor*	99201	>20/OP	w/ or w/o GT	\$30.12	N/B	N/B	\$20.33
Office Outpatient Visit, New patient, low to moderate severity*	99202	<21/IP	w/ or w/o GT	\$38.98	N/B	N/B	\$26.31
Office Outpatient Visit, New patient, low to moderate severity*	99202	<21/OP	w/ or w/o GT	\$57.79	N/B	N/B	\$39.01
Office Outpatient Visit, New patient, low to moderate severity*	99202	>20/IP	w/ or w/o GT	\$34.18	N/B	N/B	\$23.07
Office Outpatient Visit, New patient, low to moderate severity*	99202	>20/OP	w/ or w/o GT	\$50.68	N/B	N/B	\$34.21
Office Outpatient Visit, New patient, moderate severity*	99203	<21/IP	w/ or w/o GT	\$59.15	N/B	N/B	\$39.93
Office Outpatient Visit, New patient, moderate severity*	99203	<21/OP	w/ or w/o GT	\$83.14	N/B	N/B	\$56.12
Office Outpatient Visit, New patient, moderate severity*	99203	>20/IP	w/ or w/o GT	\$51.87	N/B	N/B	\$35.01
Office Outpatient Visit, New patient, moderate severity*	99203	>20/OP	w/ or w/o GT	\$72.91	N/B	N/B	\$49.21
Office Outpatient Visit, New patient, moderate to high severity*	99204	<21/IP	w/ or w/o GT	\$99.77	N/B	N/B	\$67.34
Office Outpatient Visit, New patient, moderate to high severity*	99204	<21/OP	w/ or w/o GT	\$126.75	N/B	N/B	\$85.56
Office Outpatient Visit, New patient, moderate to high severity*	99204	>20/IP	w/ or w/o GT	\$87.49	N/B	N/B	\$59.06
Office Outpatient Visit, New patient, moderate to high severity*	99204	>20/OP	w/ or w/o GT	\$111.15	N/B	N/B	\$75.03
Office Outpatient Visit, New patient, moderate to high severity*	99205	<21/IP	w/ or w/o GT	\$130.30	N/B	N/B	\$87.95
Office Outpatient Visit, New patient, moderate to high severity*	99205	<21/OP	w/ or w/o GT	\$159.46	N/B	N/B	\$107.64
Office Outpatient Visit, New patient, moderate to high severity*	99205	>20/IP	w/ or w/o GT	\$114.26	N/B	N/B	\$77.13
Office Outpatient Visit, New patient, moderate to high severity*	99205	>20/OP	w/ or w/o GT	\$139.84	N/B	N/B	\$94.39
Office Outpatient Visit, Established patient, minimal*	99211	<21/IP	w/ or w/o GT	\$7.09	N/B	N/B	\$4.79
Office Outpatient Visit, Established patient, minimal*	99211	<21/OP >20/IP	w/ or w/o GT	\$16.63	N/B	N/B	\$11.23
Office Outpatient Visit, Established patient, minimal*	99211	-	w/ or w/o GT	\$6.21	N/B	N/B	\$4.19
Office Outpatient Visit, Established patient, minimal*	99211	>20/OP	w/ or w/o GT	\$14.58	N/B	N/B	\$9.84
Office Outpatient Visit, Established patient, minor*	99212	<21/IP	w/ or w/o GT	\$19.63	N/B	N/B	\$13.25
Office Outpatient Visit, Established patient, minor*	99212	<21/OP >20/IP	w/ or w/o GT	\$33.80	N/B	N/B	\$22.82
Office Outpatient Visit, Established patient, minor*	99212	-	w/ or w/o GT	\$17.21	N/B	N/B	\$11.62
Office Outpatient Visit, Established patient, minor*	99212	>20/OP	w/ or w/o GT	\$29.64 \$20.52	N/B	N/B	\$20.01
Office Outpatient Visit, Estbl patient, low to moderate severity*	99213	<21/IP	w/ or w/o GT	\$39.53	N/B	N/B	\$26.68
Office Outpatient Visit, Estbl patient, low to moderate severity*	99213	<21/OP	w/ or w/o GT	\$56.15	N/B	N/B	\$37.90
Office Outpatient Visit, Estbl patient, low to moderate severity*	99213	>20/IP	w/ or w/o GT	\$34.66	N/B	N/B	\$23.40
Office Outpatient Visit, Estbl patient, low to moderate severity*	99213	>20/OP	w/ or w/o GT	\$49.24	N/B	N/B	\$33.24
Office Outpatient Visit, Estbl patient, moderate to high severity* Office Outpatient Visit, Estbl patient, moderate to high severity*	99214 99214	<21/IP <21/OP	w/ or w/o GT w/ or w/o GT	\$60.51	N/B N/B	N/B N/B	\$40.84 \$55.94
Office Outpatient Visit, Estbl patient, moderate to high severity*		-		\$82.87 \$52.07			
once outpatient visit, Estor patient, moderate to high severity"	99214	>20/IP	w/ or w/o GT	\$53.07	N/B	N/B	\$35.82

EFFECTIVE: 7/1/2018

DESCRIPTION	CPT® CODE	Age or Setting	Modifier	PHYSICIAN	PSYCHOLOGIST	MASTER'S LEVEL	CLINICAL NURSE SPECIALIST
Office Outpatient Visit, Estbl patient, moderate to high severity*	99214	>20/OP	w/ or w/o GT	\$72.67	N/B	N/B	\$49.05
Office Outpatient Visit, Estbl patient, moderate to high severity*	99215	<21/IP	w/ or w/o GT	\$72.07 \$85.59	N/B	N/B	\$57.77
Office Outpatient Visit, Estbl patient, moderate to high severity*	99215	<21/0P	w/ or w/o GT	\$111.76	N/B	N/B	\$75.44
Office Outpatient Visit, Estbl patient, moderate to high severity*	99215	>20/IP	w/ or w/o GT	\$75.06	N/B	N/B	\$50.67
Office Outpatient Visit, Estbl patient, moderate to high severity*	99215	>20/OP	w/ or w/o GT	\$98.01	N/B	N/B	\$66.16
Observation Care Discharge	99217	<21		\$56.43	N/B	N/B	N/B
Observation Care Discharge	99217	>20		\$30.43 \$49.48	N/B	N/B	N/B
Initial Observation Care; straightforward/low complexity	99218	<21		\$49.48 \$77.14	N/B	N/B	N/B
Initial Observation Care; straightforward/low complexity	99218	>20		\$67.65	N/B	N/B	N/B
Initial Observation Care; moderate complexity	99219	<21		\$104.95	N/B	N/B	N/B
Initial Observation Care; moderate complexity	99219	>20		\$92.03	N/B	N/B	N/B
Initial Observation Care; high complexity	99220	<21		\$143.65	N/B	N/B	N/B
Initial Observation Care; high complexity	99220	>20		\$125.97	N/B	N/B	N/B
Initial Hospital Care, low complexity*	99221	<21	w/ or w/o GT	\$78.23	N/B	N/B	N/B
Initial Hospital Care, low complexity*	99221	>20	w/ or w/o GT	\$68.60	N/B	N/B	N/B
Initial Hospital Care, moderate complexity*	99222	<21	w/ or w/o GT	\$08.00 \$105.49	N/B	N/B	N/B
Initial Hospital Care, moderate complexity*	99222	>20	w/ or w/o GT	\$105.49 \$92.51	N/B	N/B	N/B
						-	-
Initial Hospital Care, high complexity*	99223	<21	w/ or w/o GT	\$156.47	N/B	N/B	N/B
Initial Hospital Care, high complexity*	99223	>20	w/ or w/o GT	\$137.21	N/B	N/B	N/B
Subsequent Hospital Care, low complexity*	99231	<21	w/ or w/o GT	\$30.26	N/B	N/B	\$20.43
Subsequent Hospital Care, low complexity*	99231	>20	w/ or w/o GT	\$26.53	N/B	N/B	\$17.91
Subsequent Hospital Care, moderate complexity*	99232	<21	w/ or w/o GT	\$56.15	N/B	N/B	\$37.90
Subsequent Hospital Care, moderate complexity*	99232	>20	w/ or w/o GT	\$49.24	N/B	N/B	\$33.24
Subsequent Hospital Care, high complexity*	99233	<21	w/ or w/o GT	\$80.41	N/B	N/B	\$54.28
Subsequent Hospital Care, high complexity*	99233	>20	w/ or w/o GT	\$70.52	N/B	N/B	\$47.60
Observation or Inpatient Care, low complexity	99234	<21		\$102.77	N/B	N/B	N/B
Observation or Inpatient Care, low complexity	99234	>20		\$90.12	N/B	N/B	N/B
Observation or Inpatient Care, moderate complexity	99235	<21		\$130.57	N/B	N/B	N/B
Observation or Inpatient Care, moderate complexity	99235	>20		\$114.50	N/B	N/B	N/B
Observation or Inpatient Care, high complexity	99236	<21		\$168.46	N/B	N/B	N/B
Observation or Inpatient Care, high complexity	99236	>20		\$147.73	N/B	N/B	N/B
Discharge Day management -30 min or less	99238	<21		\$56.43	N/B	N/B	N/B
Discharge Day management -30 min or less	99238	>20		\$49.48	N/B	N/B	N/B
Discharge Day management -more than 30 min	99239	<21		\$83.14	N/B	N/B	N/B
Discharge Day management -more than 30 min	99239	>20		\$72.91	N/B	N/B	N/B
ER Consultation, minor	99281			\$14.98	\$13.48	N/B	N/B
ER Consultation, low to moderate complexity	99282			\$29.21	\$26.29	N/B	N/B
ER Consultation, moderate complexity	99283			\$43.70	\$39.33	N/B	N/B
ER Consultation, high complexity	99284			\$82.90	\$74.61	N/B	N/B
ER Consultation, high complexity/life threatening	99285	4-		\$122.10	\$109.89	N/B	N/B
Prolonged Service, in office or outpatient setting; 60 min	+99354	<21/IP		\$94.04	\$84.64	\$63.48	\$63.48
Prolonged Service, in office or outpatient setting; 60 min	+99354	<21/OP		\$100.59	\$90.53	\$67.90	\$67.90
Prolonged Service, in office or outpatient setting; 60 min	+99354	>20/IP		\$82.47	\$74.22	\$55.67	\$55.67
Prolonged Service, in office or outpatient setting; 60 min	+99354	>20/OP		\$88.20	\$79.38	\$59.54	\$59.54
Prolonged Service, in office or outpatient setting; addtl 30 min	+99355	<21/IP		\$70.60	\$63.54	\$47.66	\$47.66
Prolonged Service, in office or outpatient setting; addtl 30 min	+99355	-		\$76.05	\$68.45	\$51.33	\$51.33
Prolonged Service, in office or outpatient setting; addtl 30 min	+99355	>20/IP		\$61.91	\$55.72	\$41.79	\$41.79
Prolonged Service, in office or outpatient setting; addtl 30 min	+99355	>20/OP		\$66.69	\$60.02	\$45.02	\$45.02
Prolonged Service, in inpatient or observation setting; 60 min	+99356	<21		\$71.15	\$64.04	\$48.03	\$48.03
Prolonged Service, in inpatient or observation setting; 60 min	+99356			\$62.39	\$56.15	\$42.11	\$42.11
Prolonged Service, in inpatient or observation setting; addtl 30 min	+99357	<21		\$71.42	\$64.28	\$48.21	\$48.21
Prolonged Service, in inpatient or observation setting; addtl 30 min	+99357	>20		\$62.63	\$56.37	\$42.28	\$42.28
Office Emergency Services	99058			\$30.57	\$27.51	\$20.63	\$20.63
Smoking and tobacco cessation counseling; 3 to 10 min	99406	IP	HD	\$8.37	\$7.53	\$5.65	\$5.65
Smoking and tobacco cessation counseling; 3 to 10 min	99406	OP	HD	\$9.80	\$8.82	\$6.62	\$6.62
Smoking and tobacco cessation counseling; > 10 min	99407	IP	HD	\$17.45	\$15.71	\$11.78	\$11.78
Smoking and tobacco cessation counseling; > 10 min	99407	OP	HD	\$18.88	\$16.99	\$12.74	\$12.74
Alcohol/SA structured screening and brief intervention 15-30 min	99408	<21/IP		\$24.24	\$21.82	\$16.36	\$16.36
Alcohol/SA structured screening and brief intervention 15-30 min	99408	<21/OP		\$25.78	\$23.20	\$17.40	\$17.40
Alcohol/SA structured screening and brief intervention 15-30 min	99408	>20/IP		\$22.47	\$20.22	\$15.17	\$15.17
Alcohol/SA structured screening and brief intervention 15-30 min	99408	>20/OP		\$23.90	\$21.51	\$16.13	\$16.13

```
Version: 6/4/2018 Effective: 7/1/2018 Page 2 of 8
```

EFFECTIVE: 7/1/2018

DECODIDEION	CPT®					MASTER'S	
DESCRIPTION	CODE	Age or Setting	Modifier		PSYCHOLOGIST	LEVEL	SPECIALIST
Alcohol/SA structured screening and brief intervention > 30 min	99409	<21/IP <21/OP		\$48.73	\$43.86	\$32.89 \$32.76	\$32.89
Alcohol/SA structured screening and brief intervention > 30 min Alcohol/SA structured screening and brief intervention > 30 min	99409 99409	<21/0P >20/IP		\$50.02 \$45.18	\$45.02 \$40.66	\$33.76 \$30.50	\$33.76 \$30.50
Alcohol/SA structured screening and brief intervention > 30 min	99409	>20/OP		\$45.18 \$46.37	\$40.00	\$30.30 \$31.30	\$31.30
Therapeutic, prophylactic, or diagnostic injection	96372	20/0P		\$46.37 \$16.97	,341.75 N/B	351.50 Ν/Β	\$11.45
Therapeutic, prophylactic, of diagnostic injection Therapeutic or Diagnostic Injection; Intravenous Push	96374			\$38.34	N/B	N/B	\$25.88
Psychological Testing	96101	IP		\$65.55	\$59.00	N/B	N/B
Psychological Testing	96101	OP		\$68.19	\$61.37	N/B	N/B
Psychological Testing Admin by Technician	96102	IP		\$19.61	\$17.65	N/B	N/B
Psychological Testing Admin by Technician	96102	OP		\$50.92	\$45.83	N/B	N/B
Psychological Testing Admin by Computer	96103	IP		\$21.95	\$19.75	N/B	N/B
Psychological Testing Admin by Computer	96103	OP		\$22.83	\$20.54	N/B	N/B
Neurobehavioral Status Exam*	96116	IP	w/ or w/o GT	\$70.82	\$63.74	N/B	N/B
Neurobehavioral Status Exam*	96116	OP	w/ or w/o GT	\$77.55	\$69.80	N/B	N/B
Neuropsychological Testing	96118	IP		\$64.97	\$58.47	N/B	N/B
Neuropsychological Testing	96118	OP		\$80.18	\$72.16	N/B	N/B
Neuropsychological Testing Admin by Technician	96119	IP		\$19.61	\$17.65	N/B	N/B
Neuropsychological Testing Admin by Technician	96119	OP		\$65.84	\$59.26	N/B	N/B
Neuropsychological Testing Admin by Computer	96120	IP		\$21.36	\$19.22	N/B	N/B
Neuropsychological Testing Admin by Computer	96120	OP		\$39.51	\$35.56	N/B	N/B
Telehealth, originating site fee*	Q3014		GT	\$20.00	\$20.00	\$20.00	\$20.00
DECONDENCIAL			D			D 4 75	
DESCRIPTION		HCPCS CODE	Designation	M	DDIFIER	RATE	-
One on one Support in Residential - per hour Cmnty-Based Residential Group Home, Level B - Per Diem		H2027 H2020	<21		V (CSA)	\$25.61 \$146.22	
					. ,		
Cmnty-Based Residential Group Home, Level B - Per Diem		H2020 H2019	<21 Urban	пк (non-CSA)	\$146.22 \$89.00	
Crisis Stabilization, per hour		H2019 H2019	Rural			\$89.00 \$81.00	
Crisis Stabilization, per hour		H2019 H0036	Urban	w/ c	or w/o GT	\$81.00 \$30.79	
Crisis Intervention, MH - per 15 min* Crisis Intervention, MH - per 15 min*		H0036	Rural	-	or w/o GT	\$18.61	
Crisis Intervention, MH (ECO) - per 15 min*		H0036	Urban	-	or GT, 32	\$30.79	
Crisis Intervention, MH (ECO) - per 15 min*		H0036	Rural		or GT, 32	\$18.61	
		H0030	Kurai	52 (U7	\$36.53	
Assessment, Therapeutic Day Treatment for Children Assessment, Therapeutic Day Treatment for Adults*		H0032		117	or U7, GT	\$36.53	
Therapeutic Day Treatment, Child - per unit		H0035	<21	070	HA	\$36.53	
1 unit = 2 to 2.99 hours		110055	~21			J J0.JJ	
2 units = 3 to 4.99 hours							
3 units = 5 plus hours							
Day Treatment, Adult - per unit		H0035	>20		НВ	\$34.78	
1 unit 2-3.99 hours		110055	20			Ş54.70	
2 units 4-6.99 hours							
3 units 7 or more hours							
Intensive In-Home Assessment		H0031	<21			\$60.00	
Intensive In-Home Services, per hour		H2012	<21			\$60.00 \$60.00	
In-Home Behavioral Therapies for juveniles, per 15 min		H2033	<21			\$15.00	
Initial Assessment, In-Home Behavioral Therapies for juveniles, per hou	Jr	H0032	<21		UA	\$60.00	
Assessment, Psychosocial Rehab*		H0032			or U6, GT	\$24.23	
Straightforward SMI Assessment for Eligibility Determination Short For	m*	H0032		UB d	or UB, GT	\$37.00	
Complex SMI Assessment for Eligibility Determination Long Form*		H0032		UC	or UC, GT	\$75.00	
Psychosocial Rehabilitation svcs; per unit		H2017				\$24.23	
1 unit 2-3.99 hours							
2 units 4-6.99 hours							
3 units 7 or more hours			L Lula a va	119 0	or U9, GT	\$153.00	
Assessment, Intensive Community Treatment*		H0032	Urban	050	JI 05, 01	J1JJ.00	
		H0032 H0032	Rural		or U9, GT	\$139.00	
Assessment, Intensive Community Treatment*							
Assessment, Intensive Community Treatment* Assessment, Intensive Community Treatment*		H0032	Rural			\$139.00	
Assessment, Intensive Community Treatment* Assessment, Intensive Community Treatment* Intensive Community Treatment - per hour		H0032 H0039	Rural Urban			\$139.00 \$153.00	

EFFECTIVE: 7/1/2018

DESCRIPTION	HCPCS CODE	Designation	MODIFIER	RATE
Mental Health Skill Building Services	H0046	Urban		\$91.00
1 unit 1-2.99 hours				
2 units 3-4.99 hours				
3 units 5-6.99 hours				
4 units 7 or more hours				
Mental Health Skill Building Services	H0046	Rural		\$83.00
1 unit 1-2.99 hours				
2 units 3-4.99 hours				
3 units 5-6.99 hours				
4 units 7 or more hours				
Case Management, Foster Care - Per Month	T1016			\$326.50
Case Management, Mental Health, per month	H0023			\$326.50
MH Case Management Low intensity*	H0023		UB or UB, GT	\$195.90
MH Case Management High intensity*	H0023		UC or UC, GT	\$220.80
Peer Support Services - Individual (Mental Health)	H0024			\$6.50
Peer Support Services - Group (Mental Health)	H0025			\$2.70

EPSDT Therapeutic Group Home and EPSDT Residential Treatment Setting Only Services

DESCRIPTION	CPT® CODE	RATE
Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and	0359T	\$91.28
caregiver(s), includes admin of standardized and non-standardized tests, detailed behavioral history, patient observation and		
caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary		
guardian(s)/caregiver(s), and preparation of report		
Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction w/	0360T	\$36.90
interpretation & report, admin by 1 technician; 1st 30 min of tech time, face-to-face w/ the patient		
Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction w/ interp	+0361T	\$36.90
& report, admin by 1 technician; each addtl 30 min of tech time, face-to-face w/ the patient		
Family adaptive behavior treatment guidance, admin by physician or other qualified health care professional w/o the patient	0370T	\$73.97
present. Do not report in conjunction with 90791, 90792, 90846, 90847.		
Multiple-family group adaptive behavior treatment guidance, admin by physician or other qualified health care professional w/o	0371T	\$20.55
the patient present. Do not report in conjunction with 90791, 90792, 90846, 90847. Do not report if the group is larger than 8		
members.		

IACCT Services

					MASTER'S	CLINICAL NURSE
DESCRIPTION	CPT [®] CODE	Modifier	PHYSICIAN	PSYCHOLOGIST	LEVEL	SPECIALIST
IACCT Initial Assessment*	90889	HK or HK, GT	\$250.00	N/B	N/B	N/B
IACCT Follow-Up Assessment*	90889	TS or TS, GT	\$120.00	N/B	N/B	N/B
Interprofessional telephone/Internet assessment and management service; 5- 10 min of medical consultative discussion and review	99446		\$13.97	N/B	N/B	N/B
Interprofessional telephone/Internet assessment and management service; 11- 20 min of medical consultative discussion and review	99447		\$27.67	N/B	N/B	N/B
Interprofessional telephone/Internet assessment and management service; 21- 30 min of medical consultative discussion and review	99448		\$41.64	N/B	N/B	N/B
Interprofessional telephone/Internet assessment and management service; 30 min or more of medical consultative discussion and review	99449		\$55.61	N/B	N/B	N/B

ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS)

Community Based Care					
DESCRIPTION	HCPCS/Rev CODE	RATE			
Substance Use Case Management (licensed by DBHDS)	H0006	\$243.00^			
Peer Support Services - Individual (Substance Use Disorder)	T1012	\$6.50			
Peer Support Services - Group (Substance Use Disorder)	S9445	\$2.70			
Intensive Outpatient - ASAM level 2.1	H0015 or rev 0906 w/ H0015	\$250.00^			
Partial Hospitalization - ASAM level 2.5	S0201 or rev 0913 w/ S0201	\$500.00^			

EFFECTIVE: 7/1/2018

Opioid Treatment Programs (OTP) / Office Based Opioid Treatment (OBOT)

					MASTER'S	CLINICAL NURSE
DESCRIPTION	CPT [®] CODE	Age	PHYSICIAN	PSYCHOLOGIST	LEVEL	SPECIALIST
Office Outpatient Visit, Established patient, minimal	99211	<21	\$16.63	N/B	N/B	\$11.23
Office Outpatient Visit, Established patient, minimal	99211	>20	\$14.58	N/B	N/B	\$9.84
Office Outpatient Visit, Established patient, minor	99212	<21	\$33.80	N/B	N/B	\$22.82
Office Outpatient Visit, Established patient, minor	99212	>20	\$29.64	N/B	N/B	\$20.01
Office Outpatient Visit, Estbl patient, low to moderate severity	99213	<21	\$56.15	N/B	N/B	\$37.90
Office Outpatient Visit, Estbl patient, low to moderate severity	99213	>20	\$49.24	N/B	N/B	\$33.24
Office Outpatient Visit, Estbl patient, moderate to high severity	99214	<21	\$82.87	N/B	N/B	\$55.94
Office Outpatient Visit, Estbl patient, moderate to high severity	99214	>20	\$72.67	N/B	N/B	\$49.05
Office Outpatient Visit, Estbl patient, moderate to high severity	99215	<21	\$111.76	N/B	N/B	\$75.44
Office Outpatient Visit, Estbl patient, moderate to high severity	99215	>20	\$98.01	N/B	N/B	\$66.16

	CPT [®] /HCPCS		
DESCRIPTION	CODE	Modifier	RATE
Medication Assisted Treatment (MAT) induction - Physician	H0014		\$140.00
Substance Use Care Coordination	G9012		\$243.00^
Medication Administration	H0020		\$8.00
Dpioid treatment services - Individual	H0004		\$24.00
Dpioid treatment services - Group	H0005		\$7.25
Definitive drug classes - 1-7 drug classes	G0480		\$79.74
Definitive drug classes - 8-14 drug classes	G0481		\$122.99
Definitive drug classes - 15-21 drug classes	G0482		\$166.03
Definitive drug classes - 22 or more drug classes	G0483		\$215.23
Telehealth originating site facility fee*	Q3014	GT	\$20.00
Pregnancy Test	81025		\$7.30
Alcohol Breathalyzer	82075		\$5.52
Presumptive drug class screening, any drug class, direct optical observation only	80305		\$14.96
Presumptive drug class screening, any drug class, instrument assisted direct optical observation	80306		\$19.95
Presumptive drug class screening, any drug class, instrument chemistry analyzers	80307		\$79.81
TB Test	86580		\$6.73
Syphilis test, non-treponemal antibody; qualitative	86592		\$4.18
Syphilis test, non-treponemal antibody; quantitative	86593		\$4.82
Freponema pallidum	86780		\$16.02
HIV-1 test	86701		\$10.27
HIV-2 test	86702		\$9.20
HIV-1 and HIV-2 test, single result	86703		\$11.48
Hepatitis B core antibody (HBcAb); total	86704		\$13.93
Hepatitis C antibody	86803		\$16.49
EKG with at least 12 leads, with interpretation and report	93000		\$14.05
EKG tracing only, without interpretation and report	93005		\$7.02
EKG, interpretation and report only	93010		\$7.02
Medication administration in clinic - ASAM Levels 2.1 to 3.7:			
Methadone oral 5 mg	S0109		\$0.26
Buprenorphine, oral, 1 mg, per unit	J0571		\$1.00
Buprenorphine/naloxone oral <=3 mg, per unit	J0572		\$4.34
Buprenorphine/naloxone oral >=3 mg but <= 6 mg, per unit	J0573		\$7.76
Buprenorphine/naloxone oral >=6 mg but <=10 mg, per unit	J0574		\$7.76
Buprenorphine/naloxone oral >10 mg, per unit	J0575		\$15.52
Naltrexone Injection, depot form, 1 mg, per unit	J2315		\$3.25

Medication Assisted Treatment (MAT) - Outpatient Settings - non OTP/OBOT Settings

	CPT®					MASTER'S	CLINICAL NURSE
DESCRIPTION	CODE	Age	Modifier	PHYSICIAN	PSYCHOLOGIST	LEVEL	SPECIALIST
Psychotherapy w/ patient, 30 min - ASAM level 1*	90832		w/ or w/o GT	\$53.85	\$48.47	\$36.35	\$36.35
Psychotherapy w/ patient, 30 min, w/ E&M svc - ASAM level 1*	+90833		w/ or w/o GT	\$56.19	N/B	N/B	\$37.93
Psychotherapy w/ patient, 45 min - ASAM level 1*	90834		w/ or w/o GT	\$71.99	\$64.79	\$48.59	\$48.59
Psychotherapy w/ patient, 45 min, w/ E&M svc - ASAM level 1*	+90836		w/ or w/o GT	\$70.82	N/B	N/B	\$47.80
Psychotherapy w/ patient, 60 min - ASAM level 1*	90837		w/ or w/o GT	\$107.98	\$97.18	\$72.89	\$72.89
Psychotherapy w/ patient, 60 min, w/ E&M svc - ASAM level 1*	+90838		w/ or w/o GT	\$93.65	N/B	N/B	\$63.21
Family Psychotherapy w/o patient, 50 min - ASAM level 1*	90846		w/ or w/o GT	\$86.91	\$78.22	\$58.66	\$58.66
Family Psychotherapy w/ patient, 50 min - ASAM level 1*	90847		w/ or w/o GT	\$90.43	\$81.39	\$61.04	\$61.04
Group Psychotherapy - ASAM level 1*	90853		w/ or w/o GT	\$21.66	\$19.49	\$14.62	\$14.62
Office Outpatient Visit, New patient, minor	99201	<21		\$34.35	N/B	N/B	\$23.19

Version: 6/4/2018 Effective: 7/1/2018 Page 5 of 8

VA DMAS official fee schedules can be found at: <u>http://www.dmas.virginia.gov/Content_pgs/pr-ffs_new.aspx</u>

EFFECTIVE: 7/1/2018

Medication Assisted Treatment (MAT) - Outpatient Settings - non OTP/OBOT Settings (cont'd)

	CPT®					MASTER'S	CLINICAL NURSE
DESCRIPTION	CODE	Age	Modifier	PHYSICIAN	PSYCHOLOGIST	LEVEL	SPECIALIST
Office Outpatient Visit, New patient, minor	99201	>20		\$30.12	N/B	N/B	\$20.33
Office Outpatient Visit, New patient, low to moderate severity	99202	<21		\$57.79	N/B	N/B	\$39.01
Office Outpatient Visit, New patient, low to moderate severity	99202	>20		\$50.68	N/B	N/B	\$34.21
Office Outpatient Visit, New patient, moderate severity	99203	<21		\$83.14	N/B	N/B	\$56.12
Office Outpatient Visit, New patient, moderate severity	99203	>20		\$72.91	N/B	N/B	\$49.21
Office Outpatient Visit, New patient, moderate to high severity	99204	<21		\$126.75	N/B	N/B	\$85.56
Office Outpatient Visit, New patient, moderate to high severity	99204	>20		\$111.15	N/B	N/B	\$75.03
Office Outpatient Visit, New patient, moderate to high severity	99205	<21		\$159.46	N/B	N/B	\$107.64
Office Outpatient Visit, New patient, moderate to high severity	99205	>20		\$139.84	N/B	N/B	\$94.39
Office Outpatient Visit, Established patient, minimal	99211	<21		\$16.63	N/B	N/B	\$11.23
Office Outpatient Visit, Established patient, minimal	99211	>20		\$14.58	N/B	N/B	\$9.84
Office Outpatient Visit, Established patient, minor	99212	<21		\$33.80	N/B	N/B	\$22.82
Office Outpatient Visit, Established patient, minor	99212	>20		\$29.64	N/B	N/B	\$20.01
Office Outpatient Visit, Estbl patient, low to moderate severity	99213	<21		\$56.15	N/B	N/B	\$37.90
Office Outpatient Visit, Estbl patient, low to moderate severity	99213	>20		\$49.24	N/B	N/B	\$33.24
Office Outpatient Visit, Estbl patient, moderate to high severity	99214	<21		\$82.87	N/B	N/B	\$55.94
Office Outpatient Visit, Estbl patient, moderate to high severity	99214	>20		\$72.67	N/B	N/B	\$49.05
Office Outpatient Visit, Estbl patient, moderate to high severity	99215	<21		\$111.76	N/B	N/B	\$75.44
Office Outpatient Visit, Estbl patient, moderate to high severity	99215	>20		\$98.01	N/B	N/B	\$66.16
			CPT [®] /HCPCS				

DESCRIPTION	CODE	Modifier	RATE
Definitive drug classes - 1-7 drug classes	G0480		\$79.74
Definitive drug classes - 8-14 drug classes	G0481		\$122.99
Definitive drug classes - 15-21 drug classes	G0482		\$166.03
Definitive drug classes - 22 or more drug classes	G0483		\$215.23
Telehealth originating site facility fee*	Q3014	GT	\$20.00
Pregnancy Test	81025		\$7.30
Alcohol Breathalyzer	82075		\$5.52
Presumptive drug class screening, any drug class, direct optical observation only	80305		\$14.96
Presumptive drug class screening, any drug class, instrument assisted direct optical observation	80306		\$19.95
Presumptive drug class screening, any drug class, instrument chemistry analyzers	80307		\$79.81
TB Test	86580		\$6.73
Syphilis test, non-treponemal antibody; qualitative	86592		\$4.18
Syphilis test, non-treponemal antibody; quantitative	86593		\$4.82
Treponema pallidum	86780		\$16.02
HIV-1 test	86701		\$10.27
HIV-2 test	86702		\$9.20
HIV-1 and HIV-2 test, single result	86703		\$11.48
Hepatitis B core antibody (HBcAb); total	86704		\$13.93
Hepatitis C antibody	86803		\$16.49
EKG with at least 12 leads, with interpretation and report	93000		\$14.05
EKG tracing only, without interpretation and report	93005		\$7.02
EKG, interpretation and report only	93010		\$7.02

Residential and Inpatient Treatment				
DESCRIPTION	HCPCS/Rev CODE	Modifier	RATE	
Clinically managed low intensity residential services - ASAM level 3.1	H2034		\$175.00	
Clinically managed population-specific high intensity residential services - ASAM	H0010 Rev 1002	TG	\$393.50 (max)	
level 3.3				
Clinically managed high-intensity residential services (Adult) - ASMA level 3.5	H0010 Rev 1002	HB	\$393.50 (max)	
Clinically managed medium-intensity residential services	H0010 Rev 1002	HA	\$393.50 (max)	
(Adolescent) - ASAM level 3.5				
Medically monitored intensive inpatient services (Adult) - ASAM level 3.7	H2036 Rev 1002	HB	Psychiatric per	
Psychiatric Units & Freestanding Psychiatric Hospitals			diem rate	
Medically monitored intensive inpatient services (Adult) - ASAM level 3.7	H2036 Rev 1002	HB	\$393.50 (max)	
Residential Treatment Services				
Medically monitored high intensity inpatient services (Adolescent) - ASAM level	H2036 Rev 1002	HA	Psychiatric per	
3.7 Psychiatric Units & Freestanding Psychiatric Hospitals			diem rate	
Medically monitored high intensity inpatient services (Adolescent) - ASAM level	H2036 Rev 1002	HA	\$393.50 (max)	
3.7 Residential Treatment Services				
Medically managed intensive inpatient services - ASAM level 4.0	H0011 Rev 1002		Psychiatric per	
			diem or DRG	

EFFECTIVE: 7/1/2018

	Outp	atient Trea	tment				
	CPT®					MASTER'S	CLINICAL NURSE
DESCRIPTION	CODE	Age	Modifier	PHYSICIAN	PSYCHOLOGIST	LEVEL	SPECIALIST
Psychiatric Diagnostic Evaluation - no medical svcs - ASAM level 1*	90791		w/ or w/o GT	\$110.91	\$99.82	\$74.86	\$74.86
Psychotherapy w/ patient, 30 min - ASAM level 1*	90832		w/ or w/o GT	\$53.85	\$48.47	\$36.35	\$36.35
Psychotherapy w/ patient, 45 min - ASAM level 1*	90834		w/ or w/o GT	\$71.99	\$64.79	\$48.59	\$48.59
Psychotherapy w/ patient, 60 min - ASAM level 1*	90837		w/ or w/o GT	\$107.98	\$97.18	\$72.89	\$72.89
Psychiatric Diagnostic Evaluation - w/ medical svcs - ASAM level 1*	90792		w/ or w/o GT	\$124.08	N/B	N/B	\$83.75
Psychotherapy w/ patient, 30 min, w/ E&M svc - ASAM level 1*	+90833		w/ or w/o GT	\$56.19	N/B	N/B	\$37.93
Psychotherapy w/ patient, 45 min, w/ E&M svc - ASAM level 1*	+90836		w/ or w/o GT	\$70.82	N/B	N/B	\$47.80
Psychotherapy w/ patient, 60 min, w/ E&M svc - ASAM level 1*	+90838		w/ or w/o GT	\$93.65	N/B	N/B	\$63.21
Family Psychotherapy w/o patient, 50 min - ASAM level 1*	90846		w/ or w/o GT	\$86.91	\$78.22	\$58.66	\$58.66
Family Psychotherapy w/ patient, 50 min - ASAM level 1*	90847		w/ or w/o GT	\$90.43	\$81.39	\$61.04	\$61.04
Group Psychotherapy - ASAM level 1*	90853		w/ or w/o GT	\$21.66	\$19.49	\$14.62	\$14.62
Interactive Complexity Add-on - ASAM level 1*	+90785		w/ or w/o GT	\$12.00	\$10.80	\$8.10	\$8.10
Alcohol/SA structured screening and brief intervention 15-30 min -	99408	<21		\$25.78	\$23.20	\$17.40	\$17.40
ASAM level 1 Alcohol/SA structured screening and brief intervention 15-30 min - ASAM level 1	99408	>20		\$23.90	\$21.51	\$16.13	\$16.13
Alcohol/SA structured screening and brief intervention > 30 min - ASAM level 1	99409	<21		\$50.02	\$45.02	\$33.76	\$33.76
Alcohol/SA structured screening and brief intervention > 30 min - ASAM level 1	99409	>20		\$46.37	\$41.73	\$31.30	\$31.30

INACTIVE/TERMED SERVICES (see corresponding termination end dates below)

Effective Through: 3/31/2017

DESCRIPTION	HCPCS CODE	Designation	MODIFIER	RATE
Case Management Substance Abuse, per 15 min	H0006		HO or HN	\$16.50
Day Treatment Substance Abuse-for Pregnant & Postpartum Women, per day	H0015	Urban	HD	\$60.00
Day Treatment Substance Abuse-for Pregnant & Postpartum Women, per day	H0015	Rural	HD	\$54.00
Residential Substance Abuse - Pregnant & Postpartum Women	H0018	Urban	HD	\$120.00
Residential Substance Abuse - Pregnant & Postpartum Women	H0018	Rural	HD	\$108.00
Opioid Treatment services	H0020		НО	\$4.80
Opioid Treatment services	H0020		HN	\$3.60
Opioid Treatment services	H0020		HM	\$2.70
Day Treatment, Substance Abuse, per 15 min	H0047		НО	\$4.80
Day Treatment, Substance Abuse, per 15 min	H0047		HN	\$3.60
Day Treatment, Substance Abuse, per 15 min	H0047		HM	\$2.70
Crisis Intervention Substance Abuse, per 15 min (One on One Monitoring)*	H0050		HQ or HQ, GT	\$5.00
Crisis Intervention Substance Abuse, per 15 min (Crisis Counseling)*	H0050		HO or HO, GT	\$25.00
Crisis Intervention Substance Abuse, per 15 min*	H0050		HN or HN, GT	\$5.00
Crisis Intervention Substance Abuse, per 15 min*	H0050		HM or HM, GT	\$5.00
Intensive Outpatient, Substance Abuse, per 15 min	H2016		НО	\$4.80
Intensive Outpatient, Substance Abuse, per 15 min	H2016		HN	\$3.60
Intensive Outpatient, Substance Abuse, per 15 min	H2016		HM	\$2.70

Beginning 4/1/2017 the HF (Substance Abuse Program) Modifier is no longer required to be billed with the following CPT codes:

+90785, 90791, 90792, 90832, +90833, 90834, +90836, 90837, +90838, 90846, 90847, 90853, 96101, 96102, 96103, 99217, 99218, 99219, 99220, 99221, 99222, 99223, 99232, 99232, 99233, 99234, 99235, 99236, 99238, 99239

Effective Through: 4/30/2018

DESCRIPTION	HCPCS CODE	Designation	MODIFIER	RATE
Cmnty-Based Residential Group Home, Level A - Per Diem	H2022	<21	HW (CSA)	\$109.66
Cmnty-Based Residential Group Home, Level A - Per Diem	H2022	<21	HK (non-CSA)	\$109.66

EFFECTIVE: 7/1/2018

Modifier	Description	Modifier	Description
GT	Interactive telecommunication	HW	State MH Agency funded (CSA)
HA	Child/Adolescent program	TG	Complex/High Tech level of care
HB	Adult program, non-geriatric	U6	Medicaid care level 6 state defined
HD	Pregnant/Parenting Women's Program	U7	Medicaid care level 7 state defined
HF	Substance Abuse program (no longer required beginning 4/1/2017)	U8	Medicaid care level 8 state defined
нк	Specialized MH programs for high-risk pop (non-CSA)	U9	Medicaid care level 9 state defined
HM	Less than Bachelor degree level (Paraprofessional)	UA	Medicaid care level 10 state defined
HN	Bachelor degree level	UB	Medicaid care level 11 state defined
НО	Masters degree level	UC	Medicaid care level 12 state defined
HQ	Group setting	32	Mandated services - Emergency Custody Order (ECO)

Notes:

- * Procedures with the asterisk are eligible for telehealth/telemedicine under DMAS guidelines and requirements. Use the GT modifier when performing these services via telehealth. The spoke site where the member is located may only bill the Q3014 code.
- The rates for Substance Use Case Management, Substance Use Care Coordination, Opioid Treatment Programs (OTPs), Office Based Opioid Treatment (OBOT) services, Partial Hospitalization Programs and Intensive Outpatient Programs are designed to build an infrastructure for quality care. DMAS will work with Managed Care Organizations to develop accountability using financial incentives. Full payment will require providers to meet structural requirements, report quality and outcome metrics, and have a significant portion of payments at risk. Within 3 years, providers must meet thresholds for process and outcome measures. Managed Care Organizations will also be encouraged in the next 3-5 years to develop risk-based alternative payment models such as bundled payments and medical homes.
- 1. This reimbursement schedule represents the most frequently utilized Current Procedural Terminology (CPT) codes for professional services. A '+' sign denotes an add-on code that must be submitted with an applicable base procedure code.
- 2. N/B signifies that the service is non-billable for that provider type.
- 3. Magellan will not accept expired or deleted CPT/HCPCS codes. Please use and submit current CPT/HCPCS codes for all services.
- 4. Labs should only be billed if performed in-house. If patient or specimen is sent to a independent laboratory, the laboratory should bill.
- 5. Rates for all services are subject to the provisions and limitations of the Member's benefit plan including authorization requirements. Nothing in this schedule should be construed as altering Member's benefits.
- 6. If Provider submits a claim for Medically Necessary Covered Services for an amount less than the applicable rate set forth in this Agreement, Provider will be paid the lesser of the billed amount or the rate set forth in this Agreement.